{
  "nbformat": 4,
  "nbformat_minor": 0,
  "metadata": {
    "colab": {
      "provenance": []
    },
    "kernelspec": {
      "name": "python3",
      "display_name": "Python 3"
    },
    "language_info": {
      "name": "python"
    }
  },
  "cells": [
    {
      "cell_type": "markdown",
      "source": [
        "### Prepare Notebook\n",
        "Install dependencies, import packages, connect to OpenAI API."
      ],
      "metadata": {
        "id": "4pCNmbFtdttN"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "%%capture\n",
        "!pip install langchain tiktoken deeplake\n",
        "!pip install langchain-community langchain-core\n",
        "!pip install openai langchain_openai\n",
        "!pip install streamlit streamlit_chat\n",
        "!pip install faiss-cpu\n",
        "!pip install google_colab_selenium\n",
        "!pip install selenium webdriver_manager google_colab_selenium"
      ],
      "metadata": {
        "collapsed": true,
        "id": "_FFkJwWZOjZY"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "from langchain.llms import OpenAI\n",
        "from langchain.embeddings.openai import OpenAIEmbeddings\n",
        "from langchain.vectorstores import DeepLake\n",
        "from langchain_openai import ChatOpenAI\n",
        "from langchain.chains import RetrievalQA\n",
        "\n",
        "from langchain.vectorstores import FAISS\n",
        "from langchain.chains import RetrievalQAWithSourcesChain\n",
        "from langchain.text_splitter import RecursiveCharacterTextSplitter\n",
        "\n",
        "import openai"
      ],
      "metadata": {
        "id": "T2tHWx6actt0"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "import os\n",
        "import time\n",
        "import numpy as np\n",
        "from typing import List, Tuple, Dict\n",
        "\n",
        "import requests\n",
        "from bs4 import BeautifulSoup\n",
        "import google_colab_selenium as gs\n",
        "from selenium import webdriver\n",
        "from webdriver_manager.chrome import ChromeDriverManager\n",
        "from selenium.webdriver.chrome.options import Options\n",
        "from selenium.webdriver.chrome.service import Service\n",
        "\n",
        "import streamlit as st\n",
        "from streamlit_chat import message"
      ],
      "metadata": {
        "id": "7uv14pjwc70D"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "os.environ['OPENAI_API_KEY'] = \"---\"\n",
        "os.environ[\"ACTIVELOOP_TOKEN\"] = \"---\""
      ],
      "metadata": {
        "id": "29Qjw-52vgG2"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "source": [
        "### Parse Medical Data\n",
        "Medscape is a source of data."
      ],
      "metadata": {
        "id": "jPEjw7o9e_CP"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "def fetch_medscape_content(query: str, doucment_observe: int = 10) -> str:\n",
        "    \"\"\" Searches for relevant documents that may contain the answer to the query\"\"\"\n",
        "    search_url = f\"https://www.medscape.com/search/?q={query.replace(' ', '+')}&plr=ref&page=1\"\n",
        "    driver = gs.Chrome()\n",
        "    driver.get(search_url)\n",
        "    soup = BeautifulSoup(driver.page_source, 'html.parser')\n",
        "    driver.quit()\n",
        "\n",
        "    search_results = soup.find_all('div', class_='searchResult')\n",
        "    links = []\n",
        "    for div in search_results:\n",
        "        a_tag = div.find('a')\n",
        "        if a_tag and 'href' in a_tag.attrs:\n",
        "            href = a_tag['href']\n",
        "            if not href.startswith('http'):\n",
        "                          href = 'https:' + href\n",
        "            links.append(href)\n",
        "    print(f\"Found {len(links)} articles\")\n",
        "\n",
        "    documents = []\n",
        "    for link in links[:doucment_observe]:\n",
        "          article_response = requests.get(link)\n",
        "          article_soup = BeautifulSoup(article_response.text, 'html.parser')\n",
        "          content = article_soup.get_text(separator='\\n')\n",
        "          documents.append((content, link))\n",
        "    return documents\n",
        "\n"
      ],
      "metadata": {
        "id": "5vjwsCHpVh9B"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "response = requests.get(\"https://www.medscape.com/search/?q=%22symptoms%20of%20diabetes%22&plr=ref&page=1\")\n",
        "search_url=\"https://www.medscape.com/search/?q=%22symptoms%20of%20diabetes%22&plr=ref&page=1\"\n",
        "soup = BeautifulSoup(response.text, 'html.parser')\n",
        "\n",
        "chrome_options = webdriver.ChromeOptions()\n",
        "chrome_options.add_argument('--headless')\n",
        "chrome_options.add_argument('--no-sandbox')\n",
        "chrome_options.headless = True\n",
        "driver = webdriver.Chrome('chromedriver', options=chrome_options)\n",
        "driver.get(search_url)\n",
        "time.sleep(5)  # Wait for the page to load\n",
        "soup = BeautifulSoup(driver.page_source, 'html.parser')\n",
        "driver.quit()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 37
        },
        "id": "DAXEnAp4tigV",
        "outputId": "62a2e19c-05c0-4341-bdf9-9eba0616917d"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "            <div class=\"spinner-container\">\n",
              "                <div class=\"spinner\" id=\"60a1cfda-d643-4403-84e3-c62c371bf0e4-circle\"></div>\n",
              "                <div class=\"spinner-text\" id=\"60a1cfda-d643-4403-84e3-c62c371bf0e4-text\">Initializing Chromedriver</div>\n",
              "            </div>\n",
              "            <style>\n",
              "                @keyframes spin {\n",
              "                    from { transform: rotate(0deg); }\n",
              "                    to { transform: rotate(360deg); }\n",
              "                }\n",
              "\n",
              "                .spinner-container {\n",
              "                    display: flex;\n",
              "                    align-items: center;\n",
              "                    margin-bottom: 3px;\n",
              "                }\n",
              "\n",
              "                .spinner {\n",
              "                    border: 3px solid rgba(0, 0, 0, 0.1);\n",
              "                    border-left-color: lightblue;\n",
              "                    border-radius: 50%;\n",
              "                    width: 12px;\n",
              "                    height: 12px;\n",
              "                    animation: spin 1s linear infinite;\n",
              "                }\n",
              "\n",
              "                .spinner-text {\n",
              "                    padding-left: 6px;\n",
              "                }\n",
              "            </style>\n",
              "        "
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.Javascript object>"
            ],
            "application/javascript": [
              "\n",
              "            const element = document.getElementById(\"60a1cfda-d643-4403-84e3-c62c371bf0e4-circle\");\n",
              "            element.style.border = \"3px solid limegreen\";\n",
              "            element.style.animation = \"none\";\n",
              "\n",
              "            const text = document.getElementById(\"60a1cfda-d643-4403-84e3-c62c371bf0e4-text\");\n",
              "            text.innerText = \"Initialized Chromedriver\";\n",
              "        "
            ]
          },
          "metadata": {}
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "search_results = soup.find_all('div', class_='searchResult')\n",
        "links = []\n",
        "for div in search_results:\n",
        "    a_tag = div.find('a')\n",
        "    if a_tag and 'href' in a_tag.attrs:\n",
        "        href = a_tag['href']\n",
        "        if not href.startswith('http'):\n",
        "                      href = 'https:' + href\n",
        "        links.append(href)"
      ],
      "metadata": {
        "id": "7L-JCFDlD-_S"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "documents = []\n",
        "for link in links[:5]:\n",
        "      article_response = requests.get(link)\n",
        "      article_soup = BeautifulSoup(article_response.text, 'html.parser')\n",
        "      content = article_soup.get_text(separator='\\n')\n",
        "      documents.append((content, link))\n",
        "print(documents)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "cF0axSmtTT2N",
        "outputId": "d3838d53-1320-4c6e-9b93-b9a2acaa12a6"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "[(\"\\n\\n\\n\\n\\n\\nChronic Microvascular Complications of Diabetes Mellitus\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n \\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\t\\t\\tNews & Perspective\\n\\t\\t\\n\\n\\n\\n\\n\\n\\n\\n\\t\\t\\tDrugs & Diseases\\n\\t\\t\\n\\n\\n\\n\\n\\n\\n\\n\\t\\t\\tCME & Education\\n\\t\\t\\n\\n\\n\\n\\n\\n\\n\\n\\t\\t\\tVideo\\n\\t\\t\\n\\n\\n\\n\\n\\n\\n\\n\\t\\t\\tDecision Point\\n\\t\\t\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nEdition:\\n\\n\\nEnglish\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nMedscape\\n\\n\\n\\n\\n\\n\\n\\n\\t\\t\\t\\t   English\\n\\n\\n\\n\\n\\n\\n\\n\\t\\t\\t\\t   Deutsch\\n\\n\\n\\n\\n\\n\\n\\n\\t\\t\\t\\t   Español\\n\\n\\n\\n\\n\\n\\n\\n\\t\\t\\t\\t   Français\\n\\n\\n\\n\\n\\n\\n\\n\\t\\t\\t\\t   Português\\n\\n\\n\\n\\n\\n\\n\\n\\t\\t\\t\\t   UK\\nNew\\n\\n\\n\\n\\n\\n\\nUnivadis\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nLog In\\n\\n\\nSign Up It's Free!\\n\\n\\n\\n\\n\\n\\n\\n\\t\\tEnglish Edition\\n\\n\\n\\n\\n\\n\\nMedscape\\n\\n\\n\\n\\nEnglish\\n\\n\\nDeutsch\\n\\n\\nEspañol\\n\\n\\nFrançais\\n\\n\\nPortuguês\\n\\n\\nUK\\nNew\\n\\n\\n\\n\\n\\n\\n\\n\\nUnivadis\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nX\\n\\n\\n\\n\\nUnivadis\\n \\nfrom\\n \\nMedscape\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nRegister\\n\\n\\nLog In\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nNo Results\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nNo Results\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\t\\t\\t\\tNews & Perspective\\n\\t\\t\\t\\n\\n\\n\\n\\t\\t\\t\\tDrugs & Diseases\\n\\t\\t\\t\\n\\n\\n\\n\\t\\t\\t\\tCME & Education\\n\\t\\t\\t\\n\\n\\n\\n\\t\\t\\t\\tVideo\\n\\t\\t\\t\\n\\n\\n\\n\\t\\t\\t\\tDecision Point\\n\\t\\t\\t\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nclose\\n\\n\\n\\nPlease confirm that you would like to log out of Medscape.\\nIf you log out, you will be required to enter your username and password the next time you visit.\\n\\nLog out\\n\\n\\nCancel\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\xa0\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\xa0\\n\\n\\n\\n\\n\\n\\nChronic Microvascular Complications of Diabetes Mellitus\\n\\n\\n\\n\\n\\n\\n\\xa0\\n\\n\\n\\n\\n\\n\\n \\n\\n\\n\\n\\n \\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nFor More Information\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nType 1 Diabetes Mellitus\\n\\n\\n\\n\\n\\n\\n \\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nType 2 Diabetes Mellitus\\n\\n\\n\\n\\n\\n\\n \\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nDiabetic Foot Infections\\n\\n\\n\\n\\n\\n\\n \\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nDiabetic Retinopathy\\n\\n\\n\\n\\n\\n\\n \\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nDiabetic Neuropathy\\n\\n\\n\\n\\n\\n\\n \\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nDiabetic Nephropathy\\n \\n\\n\\n\\n\\n\\n\\n \\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nMore Slideshows\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nH1N1 Influenza A Virus (Swine Flu): Slideshow\\n\\n\\n\\n\\n\\n\\n \\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nAlzheimer's Disease: Slideshow\\n\\n\\n\\n\\n\\n\\n \\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nNonmelanoma Skin Cancers -- The Other Skin Cancers: Slideshow\\n\\n\\n\\n\\n\\n\\n \\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nHepatitis B: Slideshow\\n\\n\\n\\n\\n\\n\\n \\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nProviding Central Venous Access -- The Anterior Approach: Slideshow\\n\\n\\n\\n\\n\\n\\n \\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nOther Slideshows\\n\\n\\n\\n\\n\\n\\n \\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nDiabetes mellitus can lead to many acute and chronic complications. The chronic complications are mainly the result of longstanding damage to blood vessels. These complications are grouped as microvascular due to basement membrane thickening or macrovascular due to accelerated atherosclerosis. The major microvascular complications are diabetic retinopathy, nephropathy, and neuropathy. The diabetic foot ulcer shown is the result of longstanding peripheral neuropathy.\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nDiabetic retinopathy is progressive damage to the retina from longstanding diabetes mellitus that, if untreated, will lead to progressive vision loss and blindness. Microvascular basement membrane thickening impairs the diffusion of oxygen and nutrients to the retina, activating a cascade of events leading to neovascular proliferation. The abnormal growth of friable blood vessels on the retina produces microaneurysms (short arrow) that may rupture, leading to blot or flame-shaped hemorrhages (arrowhead). Hard exudates (long arrow) are caused by the breakdown of the blood-retina barrier allowing for serum proteins and lipids to leak out and accumulate on the retinal surface.\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nFluorescein angiograms allow for a better examination of the retinal vasculature. Sodium fluorescein is injected into the venous system and serial photographs of the retina are taken over time. The photographs are taken in black-and-white to provide better contrast for the vasculature. The angiogram shown demonstrates leakage of dye secondary to poor capillary integrity.\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nMacular edema is presumed to be the result of functional damage and necrosis to the retinal capillaries. It is a sign of longstanding retinal disease and over time leads to blindness. Macular edema is characterized by retinal thickening and the presence of hard exudates near the fovea, as shown. In the United States, diabetic retinopathy is the most common cause of blindness and macular edema is the major contributor.\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nDiabetic retinopathy is classified on a spectrum from nonproliferative to proliferative depending on the extent of retinal changes and the degree of microvascular growth. In advanced disease, progressive hemorrhage obscures a patient's visual fields, leading to vision loss. The image shown is an example of what a patient with advanced diabetic retinopathy may see when looking at a scene of 2 young children. Image courtesy of the National Institute of Health.\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nLaser photocoagulation provides a noninvasive means of treating microvascular retinal disease. A high-focused beam of light energy creates localized coagulation of the retina. A grid pattern of laser burns is produced to coagulate leaky blood vessels while still retaining enough retinal tissue to allow for normal vision. Image courtesy of the National Institute of Health.\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nDiabetic nephropathy is the most common cause of kidney failure in the United States. Medical management focuses on controlling hyperglycemia and high blood pressure, and keeping patients on a low protein diet. Eventually these patients will die if they do not receive peritoneal dialysis, hemodialysis, or a renal transplantation. Renal transplantation offers the best chance for medical rehabilitation but not all patients are candidates. Image courtesy of Wikimedia Commons.\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nIn the 1930s, Kimmelstiel and Wilson first described the classic diabetic lesions of nodular glomerulosclerosis that bear their names. Three major histologic changes occur. First, mesangial expansion is directly induced by hyperglycemia, perhaps via increased matrix production or glycosylation of matrix proteins. Second, glomerular basement membrane thickening occurs. Third, glomerular sclerosis is caused by intraglomerular hypertension (induced by renal vasodilatation or ischemic injury from hyaline narrowing of the vessels supplying the glomeruli).\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nDiabetic nephropathy is a clinical syndrome characterized by angiopathy of the capillaries in the kidney glomeruli, leading to progressive albuminuria, loss of glomerular filtration, and hypertension. These changes develop slowly over many years, and overt signs or symptoms may not develop until very late in the disease course. The earliest detectable changes are only evident on biopsy specimens, but as the disease advances microscopic and then gross amounts of albumin are leaked into the urine. Formal classification requires > 300 mg/day of albumin confirmed on at least 2 occasions at least 3 months apart, a progressive decline in the glomerular filtration rate, and an elevated arterial blood pressure.\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nThe exact mechanism of extracellular matrix accumulation and proteinuria is multifactorial and incompletely understood. Hyperglycemia directly leads to glycosylation product buildup, which causes extracellular matrix crosslinking. But the metabolic environment that leads to hyperglycemia is also responsible for an elevation in protein kinase C, tumor growth factor-beta, vascular endothelial growth factor, and other cytokines that lead to cellular hypertrophy, enhanced collagen synthesis, and increased vascular permeability.\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nDiabetic neuropathy is characterized by progressive loss of nerve fibers. The exact pathophysiologic mechanism is incompletely understood, but is most likely the combined result of oxidative stress, excessive neuronal intracellular glucose, and glycation end product disruption of cellular metabolism in the setting of microvascular injury. Diabetic neuropathy affects the peripheral nerves (left image), in a stocking-and-glove distribution, and the autonomic neurons (right image), within the gastrointestinal tract, bladder, and blood vessels. Patients with autonomic neuropathy may suffer from hypotension, gastroparesis, diarrhea, urinary incontinence, or urinary retention. Images courtesy of the National Institute of Health.\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nDiabetic peripheral neuropathy causes sensorial and motor symptoms. Sensorial symptoms include loss of vibration sense, temperature sense, proprioception, and reflexes as well as numbness and painful paresthesias. Because patients cannot feel their extremities, they are at risk of developing unrecognized injuries, fractures, and infections that can lead to severe ulcers or gangrene. Loss of motor function causes weakness, ocular dysfunction, and contractures. The long nerves are affected first because of the disproportionate delay in nerve conduction.\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nNeuropathic osteoarthropathy, also known as a Charcot joint, is a late complication of diabetic neuropathy. As patients lose sensation, progressive degeneration of weight-bearing joints occurs, leading to bony destruction, bone resorption, and deformity. The process is believed to be the result of the loss of proprioception and deep sensation causing recurrent trauma. Disease progression may be insidious and patients present with unsalvageable destruction.\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nAnother example of a Charcot joint from repetitive damage to the bilateral knee joints. Fragmentation and collapse of the chondral and osseous structures are shown.\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nComputed tomography scan through the level of the ankle of a Charcot joint secondary to long standing neuropathic arthropathy. Note the destruction of the articular surface (yellow arrow), disorganization of the joint, and fragmentation (red arrow).\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nPeripheral neuropathy is assessed with careful neurologic examination. Monofilament pricks are a standardized means of assessing sensorial loss. Vibration sense and reflexes are tested with a tuning fork and reflex hammer, respectively. Nerve conduction studies and electromyography may be used to detect deficits before they are clinically apparent and to rule out other etiologies. Nerve biopsies are rarely used.\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nTreatment for diabetic neuropathy begins with excellent glycemic control and regular surveillance for injuries. For pain, tricyclic antidepressants, gabapentin, pregabalin, duloxetine, topical lidocaine, or capsaicin may be used. For patients with diabetic foot ulcers, the cause of the injury should be first removed, such as poorly fitting shoes. Patients should be instructed to limit weight-bearing to the affected area. Special shoes, as shown, are designed to evenly distribute weight over the foot to prevent pressure ulcers from developing. For patients with advanced disease, antibiotics, surgical debridement, or even amputation may be necessary.\\n\\n\\n\\n\\n\\n\\n\\n\\nFor more information, see the following resources:\\n\\n\\n\\n\\nType 1 Diabetes Mellitus\\n\\n\\nType 2 Diabetes Mellitus\\n\\n\\nDiabetic Foot Infections\\n\\n\\nDiabetic Retinopathy\\n\\n\\nDiabetic Neuropathy\\n\\n\\nDiabetic Nephropathy\\n \\n\\n\\n\\n\\n\\n\\n\\n\\nMore Slideshows\\n\\n\\n\\n\\nH1N1 Influenza A Virus (Swine Flu): Slideshow\\n\\n\\nAlzheimer's Disease: Slideshow\\n\\n\\nNonmelanoma Skin Cancers -- The Other Skin Cancers: Slideshow\\n\\n\\nHepatitis B: Slideshow\\n\\n\\nProviding Central Venous Access -- The Anterior Approach: Slideshow\\n\\n\\nOther Slideshows\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nPrevious\\n\\n\\n1\\n/\\n19\\n\\n\\nNext\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n \\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\xa0\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nFind Us On\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nAbout\\n\\n\\nAbout Medscape\\n\\n\\nPrivacy Policy\\n\\n\\nEditorial Policy\\n\\n\\nCookies\\n\\n\\n\\n\\nManage Preferences\\n\\n\\n\\n\\nTerms of Use\\n\\n\\nAdvertising Policy\\n\\n\\nHelp Center\\n\\n\\n\\n\\n\\n\\nMembership\\n\\n\\nBecome a Member\\n\\n\\nAbout You\\n\\n\\nProfessional Information\\n\\n\\nNewsletters & Alerts\\n\\n\\nAdvertise\\n\\n\\n\\n\\nMarket Research\\n\\n\\n\\n\\n\\n\\nApp\\n\\n\\nMedscape\\n\\n\\n\\n\\n\\n\\nWebMD\\n Network\\n\\n\\nMedscape Live Events\\n\\n\\nWebMD\\n\\n\\nMedicineNet\\n\\n\\neMedicineHealth\\n\\n\\nRxList\\n\\n\\nWebMD Corporate\\n\\n\\nMedscape UK\\n\\n\\n\\n\\n\\n\\nEditions\\n\\n\\nEnglish\\n\\n\\nDeutsch\\n\\n\\nEspañol\\n\\n\\nFrançais\\n\\n\\nPortuguês\\n\\n\\nUK\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\t\\tAll material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.  This website also contains material copyrighted by 3rd parties.\\n\\t\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nClose\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n \\n \\n\\n\", 'http://reference.medscape.com/features/slideshow/dmc/'), ('\\n\\n\\n\\n\\n\\nClinical Findings in Diabetes Mellitus\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n \\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\t\\t\\tNews & Perspective\\n\\t\\t\\n\\n\\n\\n\\n\\n\\n\\n\\t\\t\\tDrugs & Diseases\\n\\t\\t\\n\\n\\n\\n\\n\\n\\n\\n\\t\\t\\tCME & Education\\n\\t\\t\\n\\n\\n\\n\\n\\n\\n\\n\\t\\t\\tVideo\\n\\t\\t\\n\\n\\n\\n\\n\\n\\n\\n\\t\\t\\tDecision Point\\n\\t\\t\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nEdition:\\n\\n\\nEnglish\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nMedscape\\n\\n\\n\\n\\n\\n\\n\\n\\t\\t\\t\\t   English\\n\\n\\n\\n\\n\\n\\n\\n\\t\\t\\t\\t   Deutsch\\n\\n\\n\\n\\n\\n\\n\\n\\t\\t\\t\\t   Español\\n\\n\\n\\n\\n\\n\\n\\n\\t\\t\\t\\t   Français\\n\\n\\n\\n\\n\\n\\n\\n\\t\\t\\t\\t   Português\\n\\n\\n\\n\\n\\n\\n\\n\\t\\t\\t\\t   UK\\nNew\\n\\n\\n\\n\\n\\n\\nUnivadis\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nLog In\\n\\n\\nSign Up It\\'s Free!\\n\\n\\n\\n\\n\\n\\n\\n\\t\\tEnglish Edition\\n\\n\\n\\n\\n\\n\\nMedscape\\n\\n\\n\\n\\nEnglish\\n\\n\\nDeutsch\\n\\n\\nEspañol\\n\\n\\nFrançais\\n\\n\\nPortuguês\\n\\n\\nUK\\nNew\\n\\n\\n\\n\\n\\n\\n\\n\\nUnivadis\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nX\\n\\n\\n\\n\\nUnivadis\\n \\nfrom\\n \\nMedscape\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nRegister\\n\\n\\nLog In\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nNo Results\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nNo Results\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\t\\t\\t\\tNews & Perspective\\n\\t\\t\\t\\n\\n\\n\\n\\t\\t\\t\\tDrugs & Diseases\\n\\t\\t\\t\\n\\n\\n\\n\\t\\t\\t\\tCME & Education\\n\\t\\t\\t\\n\\n\\n\\n\\t\\t\\t\\tVideo\\n\\t\\t\\t\\n\\n\\n\\n\\t\\t\\t\\tDecision Point\\n\\t\\t\\t\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nclose\\n\\n\\n\\nPlease confirm that you would like to log out of Medscape.\\nIf you log out, you will be required to enter your username and password the next time you visit.\\n\\nLog out\\n\\n\\nCancel\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nClinical Findings in Diabetes Mellitus\\n\\n\\nRomesh Khardori, MD, PhD\\n\\n\\nNovember 13, 2014\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n \\n\\n\\n\\n\\n\\n\\n\\n\\nContributor Information\\n | \\r\\n\\nReferences\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nPrevious\\n\\n\\n\\xa0of\\xa0\\n\\n\\nNext\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n \\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nPrevious\\n\\n\\n\\xa0of\\xa0\\n\\n\\nNext\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nA 45-year-old man presents with a family history of type 2 diabetes mellitus (DM), but he has no history of diabetes himself. His hemoglobin A1c (HbA1c) level is 6.1%. He has a large, protruding belly.\\n\\n\\nWhat is the significance of this patient\\'s big belly?\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nAnswer: Central adiposity/big belly may be a giveaway for an elevated risk of type 2 DM.\\n\\n\\nMost patients presenting with type 2 DM have big bellies, as do those with prediabetes. This patient has prediabetes (HbA1c 5.7-6.4%). In advanced cases, the belly may be protruding to the point where it obstructs the patient\\'s view of the feet on downward gaze.\\n\\n\\nImage courtesy of \\nWikimedia Commons\\n.\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nA young mother brings her 14-month-old baby to the clinic. She is concerned about the baby having persistent chubby cheeks and thinks her child is at risk for diabetes.\\n\\n\\nIs there any relation between chubby cheeks and diabetes?\\n\\n\\nImage courtesy of \\n {just jennifer}\\n.\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nAnswer: Chubby cheeks are strongly associated with increased visceral adiposity.\\n[1]\\n Increased visceral fat is a marker for insulin resistance and possible risk of DM. However, no studies have been done in babies to determine at what stage chubby cheeks should worry parents. In the images shown, the patient on the left is fat-fit, with a reduced amount of internal fat as compared with the obese control subject on the right.\\n\\n\\nImage courtesy of \\nWikimedia Commons\\n.\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nAn obese 24-year-old man presents to the emergency department (ED) with headache and fatigue. He has no previous history of DM. His blood glucose was 450 mg/dL, and his HbA1c is 12.3%. The physical examination is remarkable for velvety, papillomatous, hyperkeratotic and pigmented lesions in both axillae. The patient had known about the lesions for at least 3 years.\\n\\n\\nWhat is the significance of these lesions?\\n\\n\\nImage courtesy of \\nWikimedia Commons\\n.\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nAnswer: The lesions shown are typical of acanthosis nigricans, which is often discernible over the nape of the neck and may also be seen at other sites, such as flexures.\\n[2]\\n\\n\\nIn an obese patient, acanthosis nigricans lesions indicate insulin resistance, which should raise a red flag for DM or prediabetes. Treatment with metformin or insulin sensitizers (eg, pioglitazone) has been used, with limited success, to delay the onset of diabetes when dietary measures alone have not been effective. Acanthosis nigricans is also seen in patients with hypothyroidism, which must be excluded; the response to therapy can be gratifying.\\n\\n\\nImage courtesy of \\nWikimedia Commons\\n.\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nAn obese 42-year-old man has sleep apnea and newly diagnosed type 2 DM (HbA1c 8.6%). He wants to know whether his sleep apnea contributed to the development of his diabetes.\\n\\n\\nHow would you advise this patient?\\n\\n\\nImage courtesy of \\nWikimedia Commons\\n.\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nAnswer: Sleep apnea necessitating continuous positive airway pressure (CPAP) is often encountered both in prediabetes and in established type 2 DM. Two community-based studies in patients with different ethnic backgrounds have confirmed the relations among sleep-disordered breathing, insulin resistance, and glucose intolerance that are precursors to the development of diabetes.\\n[3,4]\\n Early resolution of sleep apnea or sleep-disordered breathing should be beneficial, though definitive studies are lacking.\\n\\n\\nImage courtesy of \\nHabib M\\'henni for Wikimedia Commons\\n.\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nA 44-year-old man with uncontrolled DM (HbA1c 11%) is seen in your clinic and found to have a positive prayer sign (ie, inability to close the gaps between the two opposed palmar surfaces when an attempt is made to press the hands together).\\n\\n\\nWhat is the genesis of this finding?\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nAnswer: A positive prayer sign is typical of diabetic cheiroarthropathy (also known as diabetic stiff hand or limited joint mobility [LJM] syndrome).\\n\\n\\nDiabetic cheiroarthropathy may be seen in 8-50% of patients with type 1 DM and is also seen in those with type 2 DM.\\n[5,6]\\n It is associated with and predictive of other microvascular complications. The syndrome is characterized by waxy, thick, and tight skin, similar to that seen in scleroderma. The patient is unable to fully flex or extend the fingers. Diabetic cheiroarthropathy is thought to be secondary to increased glycation of collagen in the skin, as well as decreased collagen degradation. Improvement (shown) may be seen with better glycemic control.\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nA 53-year-old man with type 2 DM of 8 years\\' duration presents to the clinic with a history of pain and a catching or locking sensation when attempting to flex the fingers of his right hand. Physical examination reveals a palpable nodule over the fourth and fifth metacarpophalangeal (MCP) joints. In addition, thenar muscle atrophy is present.\\n\\n\\nWhat are the likely diagnoses in this scenario?\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nAnswer: Thenar muscle atrophy (\\narrow\\n) may be seen in advanced diabetic neuropathy and may be a late manifestation of carpal tunnel syndrome (CTS). This patient also has features of flexor tenosynovitis (trigger finger) related to the fourth and fifth fingers of the right hand.\\n\\n\\nCTS is a consequence of entrapment neuropathy secondary to DM-induced connective-tissue changes.\\n[7]\\n It may be seen in as many as 20% of diabetic patients. The diagnosis is made on the basis of the history (eg, burning, paresthesia, and numbness in the median nerve distribution [including the first three-and-a-half fingers]) or the clinical findings. Patients with CTS do not have sensory loss in the skin overlying the thenar bulge; this is because the palmar branch of the median nerve branches off and passes over the carpal tunnel. Repetitive hand movements predispose to CTS. It is important to consider other conditions associated with CTS, such as rheumatoid arthritis, acromegaly, hypothyroidism, obesity, previous wrist injury, and pregnancy. Several clinical tests may be helpful in making the diagnosis, including the Phalen maneuver, the Tinel sign, and the Durkan test (see slides 13 and 14).\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nA 43-year-old woman with DM presents with complaints of left-hand weakness and a sensation of numbness in the left hand along the distribution of the median nerve. She has uncontrolled diabetes (HbA1c 9.6%) and has previously ignored pleas for better glycemic control. Her hand reveals left thenar atrophy, and features of proliferative retinopathy are noted.\\n\\n\\nWhat is the likely diagnosis?\\n\\n\\nImage courtesy of Science Photo Library.\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nAnswer: Left thenar atrophy in DM is commonly a complication of long-standing CTS.\\n[8]\\n\\n\\nDiabetes control is important. Because patients with type 1 DM are at higher risk for primary hypothyroidism, thyroid studies are indicated. Acromegaly is associated with CTS, and hyperglycemia may be a consequence.\\n\\n\\nThree clinical maneuvers facilitate diagnosis of CTS. To perform the Phalen maneuver, gently flex the patient\\'s wrist as far as possible, and hold it there for 60 seconds. Pain and paresthesia will occur in muscle innervated by the median nerve; the quicker the numbness starts, the more advanced the condition. To elicit the Tinel sign, gently tap the skin over the flexor retinaculum; this will induce a pins-and-needles sensation and tingling in the median nerve distribution of the palm. To perform the Durkan test, apply pressure to the palm over the nerve to elicit symptoms.\\n\\n\\nUsing a splint to keep the wrist extended often helps. Because symptoms are worst in the morning, the splint should be worn during the night. For advanced cases, surgery may be considered.\\n\\n\\nImage courtesy of Science Photo Library.\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nA 62-year-old woman with a history of type 2 DM, hypertension, and chronic renal insufficiency (stage IV chronic kidney disease) presents with ulcerative lesions of several months\\' duration located along the inner thighs and dorsal tibial regions. The lesions are firm and calcified along the edges with specks of whitish granular material in the middle of necrotic plaquelike areas. The leg does not appear swollen, and there is no clinically significant regional lymphadenopathy.\\n\\n\\nWhat is the most likely diagnosis?\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nAnswer: The lesions are highly suggestive of calciphylaxis, a poorly understood entity of skin necrosis and vascular calcification.\\n[9-11]\\n\\n\\nCalciphylaxis is uncommonly seen in uncontrolled diabetic patients, particularly in those with advanced renal complications. Its pathogenesis remains obscure. Hypercalcemia, hyperphosphatemia, chronic renal failure, hyperparathyroid state, vitamin D metabolites, vascular insufficiency, and use of immunosuppressants have all been implicated. The differential diagnosis includes chronic cellulitis, hypersensitivity vasculitis, bullous pemphigoid, brown recluse spider bite, pyoderma gangrenosum, venous ulcers, and Wegener granulomatosis. Mortality is high (60-80%), particularly in those with proximal disease; it is two times higher in those with ulcerative disease. Even though calciphylaxis is often associated with diffuse vascular pathology, it has also been reported with exclusive cutaneous involvement.\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nA 38-year-old woman with a 14-year history of type 1 DM presents for diabetes management. Physical examination reveals lesions over the shins bilaterally.\\n\\n\\nWhat is the likely diagnosis?\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nAnswer: Diabetic dermopathy (shin spots) and necrobiosis lipoidica diabeticorum (NLD) are often seen in patients with DM, possibly reflecting a form of microangiopathy.\\n\\n\\nLesions initially appear as small papules that expand rapidly into red-brown to yellow plaques with irregular borders, typically appearing along the anterior aspect of the shin. Telangectasias are visible at the lesion base. These lesions may soon turn into weeping lesions and become superinfected. The prevalence is reported at 1-2% in patients with type 1 DM. The differential diagnosis includes granuloma annulare, erythema nodosum, necrobiotic xanthogranuloma, and sarcoidosis.\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nA 62-year-old man with poorly controlled type 2 DM (HbA1c 9.2%) wakes up with an inability to lift the right foot against gravity. The patient had been sitting cross-legged while working with his laptop computer.\\n\\n\\nWhat is the likely diagnosis?\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nAnswer: Right foot drop may be noted in a patient with type 2 DM and peroneal nerve neuropathy, and in this case, compression or mechanical trauma to the common peroneal nerve is the most likely etiology.\\n[12]\\n\\n\\nThe common peroneal nerve is a branch of the sciatic nerve (L4-5, S1-3). After leaving the popliteal fossa, it crosses behind the head of the fibula and passes laterally around the neck of the fibula. It is here that the peroneal nerve is most vulnerable to compression. Foot drop is more common in diabetic patients because they already have subclinical ischemia, which is exacerbated by mechanical trauma. Males are affected more commonly than females are. The condition is often seen after sports injury, hip or knee replacement, or large weight loss (eg, after bariatric surgery). In peripheral compressive neuropathy, recovery is expected in about 3 months. The differential diagnosis includes lumbar radiculopathy, motor neuron disease, a parasagittal or subcortical cerebral lesion, Charcot foot, and habitual crossing of the legs.\\n\\n\\nImage courtesy of Science Photo Library.\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nA 56-year-old man with type 2 DM (HbA1c 8.8%) of 24 years\\' duration presents with burning, lancinating pain in the right buttock, thigh, and legs. Over the preceding 3 months, he has lost 15 lb in weight. On physical examination, there is wasting of the thigh muscles on the right side, with occasional involuntary twitching.\\n\\n\\nWhat is the likely diagnosis?\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nAnswer: Right proximal motor neuropathy (previously designated as diabetic amyotrophy).\\n\\n\\nFirst described in 1890 by Bruns, and given the name diabetic amyotrophy in 1955 by Garland, proximal motor neuropathy (also referred to as lumbosacral plexopathy) occurs in both type 1 and type 2 DM, with a peak incidence in the sixth decade of life. Weakness and atrophy of the pelvic girdle and thigh muscles are characteristic. Rapid weight loss and worsening glycemic control are common. Often, this condition is accompanied by polyneuropathy. Involuntary twitching or fasciculation may be seen. Weight gain and improved glycemic control often reduce symptom intensity. Nerve biopsies have tilted the view toward an immune mechanism that leads to endoneural vasculitis, which in turn leads to ischemia. Immunosuppressants have been used in its management.\\n[13]\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nA 56-year-old man with type 2 DM of 24 years\\' duration (HbA1c 9.8%) presents with ulcerative lesions on the soles of both feet.\\n\\n\\nWhat is the diagnosis?\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nAnswer: Diabetic foot ulcers with asymmetric peripheral vascular disease, often seen in patients with DM.\\n[14,15]\\n\\n\\nThe foot lesions shown provide an excellent illustration of asymmetrical vasculopathy and bilateral peripheral neuropathy in a diabetic patient. The ulcers at the base of the first and second toes are strongly suggestive of neuropathic ulcers (pressure points). On the left foot, there is also an ischemic ulcer at the tip of the big toe. No erythema or red flare is seen. This is highly suggestive of concomitant vascular disease. Notice also that the left foot appears pale. On the other side, the right foot has a pinkish hue, and there is a red flare surrounding the ulcers and extending deeper and inward; this reflects the inflammation that would be seen when circulation is preserved.\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nA 72-year-old man with long-standing uncontrolled diabetes and autonomic neuropathy presents to you with a painful and warm left foot.\\n\\n\\nWhat is the most likely diagnosis for this patient?\\n\\n\\nImage courtesy of \\nWikimedia Commons\\n.\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nAnswer: Charcot foot (also known as Charcot neuroarthropathy).\\n\\n\\nDiabetic neuropathy is the leading cause of Charcot foot.\\n[16, 17]\\n The foot is warm as a consequence of increased blood flow occurring in association with autonomic dysfunction. The foot is insensate, and multiple ulcerations may be seen. The medial arch is collapsed, and the foot feels like a \"bag of worms.\" Charcot foot may also be seen in other neuropathic states, such as tabes dorsalis, leprosy, spinal cord compression, multiple sclerosis, and syringomyelia.\\n\\n\\nImage courtesy of \\nWikimedia Commons\\n.\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nA 72-year-old man with a history of type 2 DM and hypertension presents with a complaint of having awakened with headache and nausea. His right eye shows clinically remarkable findings (shown).\\n\\n\\nWhat is the likely diagnosis?\\n\\n\\nImage courtesy of Science Photo Library.\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nAnswer: Right third cranial neuropathy (oculomotor nerve palsy).\\n\\n\\nThis neuropathy is signaled by mild ptosis, abduction of the eye, and downward displacement of the eye or failure to converge. Pupillary dilatation may be seen, but it may be absent (pupillary sparing) if the lesion is recovering.\\n[18,19]\\n The eye is thus displaced outward and downward. Isolated third-nerve palsy secondary to vascular disease is the most common cranial neuropathy seen in patients with DM. Hypertension may be an independent cause in some patients. Isolated third-nerve palsy is also seen in upper midbrain vascular accidents, in demyelinating lesions, and peripherally as a result of compression by carotid and posterior communicating artery aneurysms, parasellar neoplasms, sphenoidal wing neoplasms, and neoplasms of the base of the skull. With diabetes, often the recovery is complete. In this patient, symptoms reflect a cerebrovascular accident.\\n\\n\\nImage courtesy of Science Photo Library.\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nA 24-year-old male with uncontrolled type 1 DM (HbA1c 11%) presents with diabetic ketoacidosis (DKA). He also demonstrates features of cranial nerve neuropathy. \\n\\n\\nWhat is the likely diagnosis, and what is the prognosis?\\n\\n\\nImage courtesy of \\nWikimedia Commons\\n.\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nAnswer: Left seventh-nerve palsy (Bell palsy).\\n\\n\\nBell palsy may be seen in patients with DM, including those with acute decompensation such as is seen in DKA.\\n[20-23]\\n It is most often unilateral. There is a significant correlation between HbA1c level and Bell palsy; no such relation exists with hypertension or dyslipidemia. Use of statins has been linked with Bell palsy. Complete recovery is seen in almost all cases, commonly within 6 months. The postonset course of the disease in patients with DM is similar to that in patients without DM. Occasionally, bilateral Bell palsy is seen in patients with DM, but this is an exceedingly rare occurrence. When present, bilateral Bell palsy often implies a serious underlying disorder, such as Guillain-Barre syndrome, multiple cranial neuropathies, basilar meningitis (neoplastic or infectious), leukemia, syphilis, sarcoidosis, Lyme disease, HIV infection, or mononucleosis (to name only a few).\\n\\n\\nImage courtesy of Wikimedia Commons (\\nleft\\n, \\nright\\n—Patrick J. Lynch; illustrator; C. Carl Jaffe; MD; cardiologist Yale University Center for Advanced Instructional Media).\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nA patient with uncontrolled DM (HbA1c 10.4%) undergoes anterior eye chamber examination. The iris appears as shown on the slide. The patient denies experiencing any acute pain or systemic symptoms.\\n\\n\\nWhat is the diagnosis?\\n\\n\\nImage courtesy of Science Photo Library.\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nAnswer: Rubeosis iridis (vascular invasion/neovascularization of the iris).\\n\\n\\nThis condition is seen in uncontrolled DM and may precipitate glaucoma. Symptoms are usually related to glaucoma. Rubeosis iridis is usually associated with a disease process in the retina that entails the retina becoming ischemic and releasing a variety of angiogenesis factors, such as vascular endothelial growth factor (VEGF). These factors promote angiogenesis in areas that do not normally have vessels, such as the iris. In the early stages, neovascularization can be reversed by means of prompt panretinal photo coagulation (PRP) or injection of anti-VEGF medications.\\n[24]\\n\\n\\nImage courtesy of Science Photo Library.\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nA young female patient with DM (HbA1c 8.9%) of 8 years\\' duration undergoes a physical examination, the results of which are completely normal. Her primary care provider asks you take a look at the patient\\'s most recent photograph (shown), which, he thinks, demonstrates an abnormality that was not seen earlier.\\n\\n\\nWhat is the diagnosis, and how is it linked to diabetes?\\n\\n\\nImage courtesy of \\nWikimedia Commons\\n.\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nAnswer: Heterochromia iridum (dissimilar colors of the irises).\\n\\n\\nThis condition may be seen in DM after inflammation of iris in patients with rubeosis iridis or glaucoma; it may also be seen in patients with glaucoma who are using latanoprost eyedrops.\\n[25,26]\\n The treated eye shows increased pigmentation. Heterochromia of the iris can also be a benign congenital condition seen in as many as six of every 1000 eyes examined. It is often subtle and may go unnoticed. Acquired iris heterochromia is always due to disease affecting eyes or loss of sympathetic innervation on the affected side.\\n\\n\\nImage courtesy of \\nWikimedia Commons\\n.\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nSome patients with DM show a clinical picture similar to the one shown on the slide, in which a right miotic irregular pupil does not react to direct light (pupillary reaction) but responds to accommodation.\\n\\n\\nWhat is this phenomenon called?\\n\\n\\nImage courtesy of \\nWikimedia Commons\\n.\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nAnswer: Argyll Robertson pupil (ARP).\\n\\n\\nARP is characterized by a small pupil, failure of pupillary constriction (pupillary response) in response to light, and preservation of accommodation response.\\n[27]\\n Initially considered pathognomonic for neurosyphilis, ARP has since been observed in sarcoidosis, multiple sclerosis, and occasionally DM. The pupil\\'s better response to accommodation than to light stimuli is a reflection of a vascular lesion that affects more dorsally located fibers that subserve the light response. Two mnemonics may be helpful for remembering the characteristics of this condition: The acronym ARP can also be thought of as short for \"accommodation reflex present,\" and if it is reversed, the resulting acronym, PRA, can be thought of as short for \"pupillary reaction (to light) absent.\"\\n\\n\\nImage courtesy of \\nWikimedia Commons\\n.\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nGustatory sweating (sweating of the face, head, and neck at the sight or smell of food) may be seen in patients with DM and autonomic neuropathy, in whom it is a relatively common phenomenon.\\n[28,29]\\n Its presence indicates possible concurrent diabetic complications. Glycemic control is not related to the severity of symptoms. Reversal of gustatory sweating has been reported with renal transplantation in those with end-stage diabetic nephropathy; it has been reported in the absence of nephropathy as well.\\n\\n\\nImage Courtesy of \\nVox Efx\\n, inset \\nWikimedia Commons\\n.\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nMore Slideshows\\n\\n\\n\\n\\n\\n\\n\\n\\nChronic Microvascular Complications of Diabetes Mellitus\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nClassifying Pressure Ulcers: 15 Cases to Test Your Skills\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nClinical Presentations of Lung Cancer: Slideshow\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nThe Case of the Middle-Aged Woman With Sudden Unilateral Vision Loss\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nPediatric Concussion and Other Traumatic Brain Injuries\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nMore Slideshows\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nFor More Information\\n\\n\\n\\n\\n\\n\\n\\n\\nType 2 Diabetes Mellitus\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nType 2 Diabetes ADA Diagnosis Guideline\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nGestational Diabetes Testing Protocol\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nType 1 Diabetes Mellitus\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nDiabetes Insipidus\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nType 2 Diabetes and TCF7L2\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nCLOSE WINDOW\\n\\n\\n\\n\\n\\n\\nContributor Information\\n\\n\\nAuthor\\n\\n\\nRomesh Khardori, MD, PhD, FACP\\n\\r\\n\\r\\nProfessor of Medicine\\n\\r\\nDivision of Endocrinology, Diabetes & Metabolism\\n\\r\\n\\r\\nProgram Director, Endocrinology Metabolism Fellowship Program\\n\\r\\n\\r\\nEastern Virginia Medical School\\n\\r\\n\\r\\nNorfolk, VA\\n\\n\\nDisclosure: Romesh Khardori, MD, PhD, FACP, has disclosed no relevant financial relationships.\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nCLOSE WINDOW\\n\\n\\n\\n\\n\\n\\nReferences\\n\\n\\n\\n\\nLevine JA, Ray A, Jensen MD. Relation between chubby cheeks and visceral fat. \\nN Engl J Med.\\n 1998;339:1946.\\n\\n\\nSchilling WHK, Crook MA. Cutaneous stigmata associated with insulin resistance and increased cardiovascular risk. \\nInt J Dermatol.\\n 2014;53:1062-9.\\n\\n\\nLindberg E, Theorell-Haglow J, Svensson M, et al. Sleep apnea and glucose metabolism: a long -term follow up in a community-based sample. \\nChest.\\n 2012;142(4):935-42.\\n\\n\\nTanno S, Tanigawa T, Saito I, et al. Sleep-related hypoxemia and glucose intolerance: a community-based study. \\nSleep Med.\\n Oct 2014;15(10):1212-8.\\n\\n\\nLundbeck K. Stiff hands in long-term diabetes. \\nActa Med Scand.\\n 1957;158(6):447-51.\\n\\n\\nSerban AL, Udrea GF. Rheumatic manifestations in diabetic patients. \\nJ Med Life.\\n 2012;5(3):252-7.\\n\\n\\nKim RP, Edelman SV, Kim DD. Musculoskeletal complications of diabetes mellitus. \\nClin Diabetes.\\n 2001;3:132.\\n\\n\\nKim PT, Lee HJ, Kim TG, Jean IH. Current approaches for carpal tunnel syndrome. \\nClin Orthop Surg.\\n 2014;6:253-7.\\n\\n\\nWeenig RH, Sewell LD, Davis MD, McCarthy JT, Pittelkow MR. Calciphylaxis: natural history, risk factor analysis, and outcome. \\nJ Am Acad Dermatol.\\n 2007;56(4):569-79.\\n\\n\\nNunley JR. Calciphylaxis. \\nMedscape Drugs & Diseases.\\n Updated July 21, 2014; Accessed September 15, 2014. Available at \\nhttp://emedicine.medscape.com/article/1095481-overview\\n.\\n\\n\\nAndersen LK, Lehman JS, Davis MDP. Calciphylaxis is a cutaneous process without involvement of internal organs in a retrospective study of postmortem findings in three patient. \\nActa Derm Venereol.\\n 2014;94:298-302.\\n\\n\\nKoffman BM, Greenfield LJ, Ali II, Pirzada NA. Neurologic complications after surgery for obesity. \\nMuscle Nerve.\\n 2006;33(2):166-176.\\n\\n\\nDyck PJ, Winderbank AJ. Diabetic and non diabetic lumboscaral radiculoplexus neuropathies. New insights into pathophysiology and treatment. \\nMuscle Nerve.\\n 2002;25:477-491.\\n\\n\\nJeffcoate W, Harding KG. Diabetic foot ulcers. \\nLancet.\\n 2003;361:1545-51.\\n\\n\\nMonteiro-Soares M, Boyko EJ, Ribeiro J, et al. Predictive factors for diabetic foot ulcers—a systemic review. \\nDiab Metab Res Rev.\\n 2012;28(7):574-600.\\n\\n\\nRogers LC, Frykberg RG, Armstrong DG, et al. The Charcot foot in diabetes. \\nDiabetes Care.\\n 2011;34:123-9.\\n\\n\\nMascarenhas JV, Jude EB. Pathogenesis and medical management of diabetic Charcot neuroarthropathy. \\nMed Clin N Am.\\n 2013;97:857-72.\\n\\n\\nGoodwin J. Oculomotor nerve palsy. \\nMedscape Drugs & Diseases.\\n Updated February 20, 2014; Accessed September 15, 2014. Available at \\nhttp://emedicine.medscape.com/article/1198462-overview\\n.\\n\\n\\nBickerstaff ER. \\nNeurological Examination in Clinical Practice.\\n 3rd ed. Oxford, England: Blackwell Scientific Publications; 1973.\\n\\n\\nRiga M, Kefalidis G, Danielides V. The role of diabetes mellitus in the clinical presentation and prognosis of Bell\\'s palsy. \\nJ Am Board Fam Med.\\n 2012;25:819-26.\\n\\n\\nHung SH, Wang KH, Lin HC, Chung SD. Association between statin use and Bell\\'s palsy: a population-based study. \\nDrug Saf.\\n 2014 Sep;37(9):735-42.\\n\\n\\nKamaratos A, Kokkoris S, Protopsaltis J, et al. Simultaneous bilateral facial palsy in a diabetic patient. \\nDiabetes Care.\\n 2004;27:623-4.\\n\\n\\nPothiawala S, Lateef F. Bilateral facial nerve palsy: a diagnostic dilemma. \\nCase Rep Emerg Med.\\n 2012;2012:458371.\\n\\n\\nDavidorf FH, Mouser JG, Derick RJ. Rapid improvement of rubeosis iridis from a single bevacizumab (Avastin) injection. \\nRetina.\\n 2006;26(3):354-6.\\n\\n\\nOlitsky SE et al. Abnormalities of pupil and iris. In: Kliegman RM et al (Eds). \\nNelson Textbook of Pediatrics.\\n 19th ed. Philadelphia: Saunders Elsevier; 2011.\\n\\n\\nTeus MA, Arranz-Marquez M, Suescun PL. Incidence of iris colour changes in latanoprost treated eyes. \\nBr J Ophthalmol.\\n 2000;86:1085-8.\\n\\n\\nSyed SA, Saberi A. Argyll Robertson pupil. \\nHosp Physician.\\n 1999 Jan;35(1):21-2.\\n\\n\\nWatkins PJ. Facial sweating after food: a new sign of diabetic autonomic neuropathy. \\nBMJ.\\n 1973;1:583-7.\\n\\n\\nBlair DI, Sagel J, Taylor I. Diabetic gustatory sweating. \\nSouth Med J.\\n 2002;95(3):360-2.\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n \\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\xa0\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nFind Us On\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nAbout\\n\\n\\nAbout Medscape\\n\\n\\nPrivacy Policy\\n\\n\\nEditorial Policy\\n\\n\\nCookies\\n\\n\\n\\n\\nManage Preferences\\n\\n\\n\\n\\nTerms of Use\\n\\n\\nAdvertising Policy\\n\\n\\nHelp Center\\n\\n\\n\\n\\n\\n\\nMembership\\n\\n\\nBecome a Member\\n\\n\\nAbout You\\n\\n\\nProfessional Information\\n\\n\\nNewsletters & Alerts\\n\\n\\nAdvertise\\n\\n\\n\\n\\nMarket Research\\n\\n\\n\\n\\n\\n\\nApp\\n\\n\\nMedscape\\n\\n\\n\\n\\n\\n\\nWebMD\\n Network\\n\\n\\nMedscape Live Events\\n\\n\\nWebMD\\n\\n\\nMedicineNet\\n\\n\\neMedicineHealth\\n\\n\\nRxList\\n\\n\\nWebMD Corporate\\n\\n\\nMedscape UK\\n\\n\\n\\n\\n\\n\\nEditions\\n\\n\\nEnglish\\n\\n\\nDeutsch\\n\\n\\nEspañol\\n\\n\\nFrançais\\n\\n\\nPortuguês\\n\\n\\nUK\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\t\\tAll material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.  This website also contains material copyrighted by 3rd parties.\\n\\t\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nClose\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n \\n \\n\\n\\n\\n', 'http://reference.medscape.com/features/slideshow/diabetes-mellitus'), ('\\n\\n\\n\\n\\n\\nDiabetic Neuropathy: Practice Essentials, Background, Anatomy\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\t\\t\\tNews & Perspective\\n\\t\\t\\n\\n\\n\\n\\n\\n\\n\\n\\t\\t\\tDrugs & Diseases\\n\\t\\t\\n\\n\\n\\n\\n\\n\\n\\n\\t\\t\\tCME & Education\\n\\t\\t\\n\\n\\n\\n\\n\\n\\n\\n\\t\\t\\tVideo\\n\\t\\t\\n\\n\\n\\n\\n\\n\\n\\n\\t\\t\\tDecision Point\\n\\t\\t\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nEdition:\\n\\n\\nEnglish\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nMedscape\\n\\n\\n\\n\\n\\n\\n\\n\\t\\t\\t\\t   English\\n\\n\\n\\n\\n\\n\\n\\n\\t\\t\\t\\t   Deutsch\\n\\n\\n\\n\\n\\n\\n\\n\\t\\t\\t\\t   Español\\n\\n\\n\\n\\n\\n\\n\\n\\t\\t\\t\\t   Français\\n\\n\\n\\n\\n\\n\\n\\n\\t\\t\\t\\t   Português\\n\\n\\n\\n\\n\\n\\n\\n\\t\\t\\t\\t   UK\\nNew\\n\\n\\n\\n\\n\\n\\nUnivadis\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nLog In\\n\\n\\nSign Up It\\'s Free!\\n\\n\\n\\n\\n\\n\\n\\n\\t\\tEnglish Edition\\n\\n\\n\\n\\n\\n\\nMedscape\\n\\n\\n\\n\\nEnglish\\n\\n\\nDeutsch\\n\\n\\nEspañol\\n\\n\\nFrançais\\n\\n\\nPortuguês\\n\\n\\nUK\\nNew\\n\\n\\n\\n\\n\\n\\n\\n\\nUnivadis\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nX\\n\\n\\n\\n\\nUnivadis\\n \\nfrom\\n \\nMedscape\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nRegister\\n\\n\\nLog In\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nNo Results\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nNo Results\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\t\\t\\t\\tNews & Perspective\\n\\t\\t\\t\\n\\n\\n\\n\\t\\t\\t\\tDrugs & Diseases\\n\\t\\t\\t\\n\\n\\n\\n\\t\\t\\t\\tCME & Education\\n\\t\\t\\t\\n\\n\\n\\n\\t\\t\\t\\tVideo\\n\\t\\t\\t\\n\\n\\n\\n\\t\\t\\t\\tDecision Point\\n\\t\\t\\t\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nclose\\n\\n\\n\\nPlease confirm that you would like to log out of Medscape.\\nIf you log out, you will be required to enter your username and password the next time you visit.\\n\\nLog out\\n\\n\\nCancel\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\t\\t\\thttps://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache=aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvMTE3MDMzNy1vdmVydmlldw==\\n\\n\\n\\n\\n\\n\\nprocessing....\\n\\n\\n \\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nDrugs & Diseases\\n\\n\\n>\\n\\n\\nEndocrinology\\n\\n\\n\\n\\n\\n\\nDiabetic Neuropathy\\n\\n\\n\\n\\n\\n      Updated: Aug 24, 2021\\n     \\n\\n\\n\\n\\n\\n\\n Author: Dianna Quan, MD; Chief Editor: Romesh Khardori, MD, PhD, FACP\\xa0 \\nmore...\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nShare\\n\\n\\nPrint\\n\\n\\nFeedback\\n\\n\\n\\n\\n\\n\\n\\n\\nClose\\n\\n\\n\\n\\n\\n\\nFacebook\\n\\n\\nTwitter\\n\\n\\nLinkedIn\\n\\n\\nWhatsApp\\n\\n\\nEmail\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nSections\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nDiabetic Neuropathy\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n            Sections \\n            \\nDiabetic Neuropathy\\n\\n\\n\\n\\nOverview\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nPractice Essentials\\n\\n\\nBackground\\n\\n\\nAnatomy\\n\\n\\nPathophysiology\\n\\n\\nEtiology\\n\\n\\nEpidemiology\\n\\n\\nPrognosis\\n\\n\\nPatient Education\\n\\n\\nShow All\\n\\n\\n\\n\\nPresentation\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nHistory\\n\\n\\nPhysical Examination\\n\\n\\nClassification of Diabetic Neuropathy\\n\\n\\nStaging\\n\\n\\nShow All\\n\\n\\n\\n\\n\\n\\nDDx\\n\\n\\nWorkup\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nApproach Considerations\\n\\n\\nHemoglobin A1c and Fasting Plasma Glucose\\n\\n\\nBasic Laboratory Screening Tests\\n\\n\\nElectromyography and Nerve Conduction Studies\\n\\n\\nElectrophysiologic Studies\\n\\n\\nMRI and CT\\n\\n\\nNuclear Imaging\\n\\n\\nDoppler Imaging\\n\\n\\nMicrodialysis\\n\\n\\nElectrocardiography\\n\\n\\nNerve and Skin Biopsy\\n\\n\\nFuture Approaches\\n\\n\\nShow All\\n\\n\\n\\n\\nTreatment\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nApproach Considerations\\n\\n\\nGlycemic Control\\n\\n\\nDiabetic Neuropathic Pain Management\\n\\n\\nPain Control in Pregnancy\\n\\n\\nDiabetic Gastroparesis\\n\\n\\nDietary Supplements\\n\\n\\nExperimental Therapies\\n\\n\\nTreatment of Autonomic Dysfunction\\n\\n\\nSurgical Treatment\\n\\n\\nPancreatic Transplantation\\n\\n\\nRehabilitation\\n\\n\\nComplications of Disease\\n\\n\\nConsultations\\n\\n\\nLong-Term Monitoring\\n\\n\\nShow All\\n\\n\\n\\n\\nMedication\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nMedication Summary\\n\\n\\nNonsteroidal Anti-Inflammatory Drugs (NSAIDs)\\n\\n\\nAnalgesics, Topical\\n\\n\\nAnticonvulsant\\n\\n\\nAntidepressant, Tricyclic\\n\\n\\nAntidepressant, Selective Serotonin/norepinephrine Reuptake Inhibitor (SSNRI)\\n\\n\\nAntidepressant, Serotonin Reuptake Inhibitor\\n\\n\\nAntiarrhythmic Agent, Class I-b\\n\\n\\nProkinetic Agents\\n\\n\\nAntidepressant, Tetracyclic\\n\\n\\nSynthetic Adrenocortical Steroids\\n\\n\\nCholinergic Agent\\n\\n\\nLaxative, Bowel Evacuant\\n\\n\\nShow All\\n\\n\\n\\n\\n\\n\\nQuestions & Answers\\n\\n\\nTables\\n\\n\\nReferences\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n      Overview\\n     \\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nPractice Essentials\\n\\n\\n\\n\\n\\n\\nDiabetic neuropathy is the most common complication of diabetes mellitus (DM), affecting as many as 50% of patients with type 1 and type 2 DM. Diabetic peripheral neuropathy involves the presence of symptoms or signs of peripheral nerve dysfunction in people with diabetes after other possible causes have been excluded.\\n\\n\\n [\\n1\\n, \\n2\\n, \\n3\\n] \\nIn some cases, patients are symptomatic long before routinely performed clinical examination reveals abnormalities. Of all treatments, tight and stable glycemic control is probably the most important for slowing the progression of neuropathy.\\n\\n\\n [\\n4\\n] \\n\\xa0\\n\\n\\nSigns and symptoms of diabetic neuropathy\\n\\n\\nIn type 1 DM, distal polyneuropathy typically becomes symptomatic after many years of chronic prolonged hyperglycemia, whereas in type 2, it may be apparent after only a few years of known poor glycemic control or even at diagnosis. Symptoms include the following:\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nSensory – Negative or positive, diffuse or focal; usually insidious in onset and showing a stocking-and-glove distribution in the distal extremities\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nMotor – Distal, proximal, or more focal weakness, sometimes occurring along with sensory neuropathy (sensorimotor neuropathy)\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nAutonomic – Neuropathy that may involve the cardiovascular, gastrointestinal, and genitourinary systems and the sweat glands\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nPhysical examination should include the following assessments:\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nPeripheral neuropathy testing – Gross light touch and pinprick sensation; vibratory sense; deep tendon reflexes; strength testing and muscle atrophy; dorsal pedal and posterior tibial pulses; skin assessment; Tinel testing; cranial nerve testing\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nAutonomic neuropathy testing – Objective evaluation of cardiovagal, adrenergic, and sudomotor function in a specialized autonomic laboratory; may be preceded by bedside screening to assess supine and upright blood pressure and heart rate, with measurement of sinus arrhythmia ratio\\n\\n\\n\\n\\n\\n\\nTwo classification systems for diabetic neuropathy are the Thomas system and the symmetrical-versus-asymmetrical system. The Thomas system (modified) is as follows:\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nHyperglycemic neuropathy\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nGeneralized symmetrical polyneuropathies\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nSensory neuropathy\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nSensorimotor neuropathy\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nAutonomic neuropathy\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nFocal and multifocal neuropathies\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nSuperimposed chronic inflammatory demyelinating polyneuropathy\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nDistal symmetrical sensorimotor polyneuropathy is commonly defined according to the following 3 key criteria:\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nThe patient must have diabetes mellitus consistent with a widely accepted definition\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nSeverity of polyneuropathy should be commensurate with duration and severity of diabetes\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nOther causes of sensorimotor polyneuropathy must be excluded\\n\\n\\n\\n\\n\\n\\n\\n\\nPure autonomic diabetic neuropathy is rare.\\n\\n\\n\\n\\nAsymmetrical neuropathies include the following:\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nMedian neuropathy of the wrist (carpal tunnel syndrome)\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nOther single or multiple limb mononeuropathies\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nThoracic radiculoneuropathy\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nLumbosacral radiculoplexus neuropathy\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nCervical radiculoplexus neuropathy\\n\\n\\n\\n\\n\\n\\n\\n\\nDiabetic polyneuropathy is commonly staged as follows:\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nNO - No neuropathy\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nN1a - Signs but no symptoms of neuropathy\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nN2a - Symptomatic mild diabetic polyneuropathy; sensory, motor, or autonomic symptoms; patient is able to heel-walk\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nN2b - Severe symptomatic diabetic polyneuropathy; patient is unable to heel-walk\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nN3 - Disabling diabetic polyneuropathy\\n\\n\\n\\n\\n\\n\\n\\n\\nSee \\nClinical Presentation\\n for more detail.\\n\\n\\n\\n\\nDiagnosis of diabetic neuropathy\\n\\n\\nLaboratory tests that may be helpful include the following:\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nFasting plasma glucose\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nHemoglobin A1c\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nComplete blood count\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nComplete metabolic panel (electrolytes and liver function panel)\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nVitamin B-12 and folate levels\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nThyroid function tests\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nErythrocyte sedimentation rate\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nC-reactive protein\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nSerum protein electrophoresis with immunofixation electrophoresis\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nAntinuclear antibody\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nAnti-SSA and SSB antibodies\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nRheumatoid factor\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nParaneoplastic antibodies\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nRapid plasma reagin\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nGenetic screens\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nHematology screen (for anemia)\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nSequential multiple analysis-7 (renal function and electrolyte imbalances)/complete metabolic panel (CMP)\\n\\n\\n\\n\\n\\n\\n\\n\\nOther diagnostic modalities that may be considered are as follows:\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nElectromyography and nerve conduction velocity testing\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nElectrophysiologic studies\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nMagnetic resonance imaging\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nComputed tomography (including single-photon emission computed tomography)\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nNuclear imaging\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nDoppler imaging\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nMicrodialysis\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nElectrocardiography\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nNerve and skin biopsy (now rarely recommended for clinical purposes)\\n\\n\\n\\n\\n\\n\\n\\n\\nSee \\nWorkup\\n for more detail.\\n\\n\\n\\n\\nManagement of diabetic neuropathy\\n\\n\\nKey components of the management of diabetic neuropathy include the following:\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nFoot care, including regular follow-up, patient education, and referral as appropriate\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nTight, stable glycemic control (most important for slowing progression of neuropathy)\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nPain management (eg, with pregabalin, gabapentin, sodium valproate, dextromethorphan, morphine sulfate, tramadol, oxycodone, duloxetine, topical capsaicin, transdermal lidocaine)\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nTreatment of diabetic gastroparesis (eg, with erythromycin, cisapride [not available in the United States], metoclopramide, polyethylene glycol 3350, tegaserod [currently available only on an emergency basis])\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nExperimental therapies include aldose reductase inhibitors, alpha-lipoic acid, actovegin, and spinal cord stimulators.\\n\\n\\n\\n\\n\\n\\n\\n\\nTreatment of autonomic dysfunction must address the following:\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nErectile dysfunction\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nOrthostatic hypotension\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nGustatory sweating\\n\\n\\n\\n\\n\\n\\n\\n\\nSurgical treatment may be considered as follows:\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nAggressive debridement or amputation for recalcitrant foot necrosis or infection\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nJejunostomy for intractable gastroparesis\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nImplantation of a penile prosthesis for ongoing impotence\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nBracing, special boots, or, in some cases, surgery for Charcot foot\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nPancreatic transplantation for diabetes with end-stage renal disease\\n\\n\\n\\n\\n\\n\\n\\n\\nSee \\nTreatment\\n and \\nMedication\\n for more detail.\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n         Next: \\n        \\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nBackground\\n\\n\\n\\n\\n\\n\\nNeuropathies are characterized by a progressive loss of nerve fiber function. A widely accepted definition of diabetic peripheral neuropathy is \"the presence of symptoms and/or signs of peripheral nerve dysfunction in people with diabetes after exclusion of other causes.\"\\n\\n\\n [\\n5\\n, \\n6\\n] \\n\\n\\n\\n\\nNeuropathies are the most common complication of diabetes mellitus (DM), affecting up to 50% of patients with type 1 and type 2 DM. In \\ntype 1 diabetes mellitus\\n, distal polyneuropathy typically becomes symptomatic after many years of chronic prolonged hyperglycemia. Conversely, patients with \\ntype 2 diabetes mellitus\\n may present with distal polyneuropathy after only a few years of known poor glycemic control; sometimes, these patients already have neuropathy at the time of diagnosis. (See Clinical Presentation.)\\n\\n\\n\\n\\nNeuropathies severely decrease patients\\' quality of life (QOL). Furthermore, while the primary symptoms of neuropathy can be highly unpleasant, the secondary complications (eg, falls, \\nfoot ulcers\\n, cardiac arrhythmias, and ileus) are even more serious and can lead to fractures, amputations, and even death in patients with DM.\\n\\n\\n\\n\\nSince diabetic neuropathy can manifest with a wide variety of sensory, motor, and autonomic symptoms, a structured list of symptoms can be used to help screen all diabetic patients for possible neuropathy (see History). Physical examination of patients with suspected distal sensory motor or focal (ie, entrapment or noncompressive) neuropathies should include assessments for both peripheral and autonomic neuropathy (see Physical Examination).\\n\\n\\n\\n\\nMultiple consensus panels recommend the inclusion of electrophysiologic testing in the evaluation of diabetic neuropathy. An appropriate array of electrodiagnostic tests includes both nerve conduction testing and needle EMG of the most distal muscles usually affected. (See Workup.)\\n\\n\\n\\n\\nManagement of diabetic neuropathy should begin at the initial diagnosis of diabetes. The primary care physician needs to be alert for the development of neuropathy—or even its presence at the time of initial diabetes diagnosis—because failure to diagnose diabetic polyneuropathy can lead to serious consequences, including disability and amputation. In addition, the primary care physician is responsible for educating patients about the acute and chronic complications of diabetes (see Patient Education). Patients with diabetic peripheral neuropathy require more frequent follow-up, with particular attention to foot inspection to reinforce the need for regular self-care. (See Treatment Strategies and Management.)\\n\\n\\n\\n\\nManagement of diabetic neuropathy includes 2 approaches: therapies for symptomatic relief and those that may slow the progression of neuropathy. Of all treatments, tight and stable glycemic control is probably the most important for slowing the progression of neuropathy. Many medications are available for the treatment of diabetic neuropathic pain, although most of them are not specifically approved by the United States Food and Drug Administration for this use. Nonpharmacologic treatment includes rehabilitation, which may comprise physical, occupational, speech, and recreational therapy. (See Medication.)\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n         Previous\\n        \\n\\n\\n\\n         Next: \\n        \\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nAnatomy\\n\\n\\n\\n\\n\\n\\nA review of the anatomy of the peripheral nervous system can facilitate understanding of the classification of diabetic peripheral neuropathy. Peripheral neurons can be categorized broadly as motor, sensory, or autonomic.\\n\\n\\n\\n\\nMotor neurons originate in the central nervous system (CNS) and extend to the anterior horn of the spinal cord. From the anterior horn, they exit the spinal cord (via ventral roots) and combine with other fibers in the brachial or lumbar plexuses and innervate their target organs through peripheral nerves.\\n\\n\\n\\n\\nSensory neurons originate at the dorsal root ganglia (which lie outside the spinal cord) and follow a similar course with motor neurons. Sensory neurons are subdivided into categories according to the sensory modality they convey (see the Table below).\\n\\n\\n\\n\\nAutonomic neurons consist of sympathetic and parasympathetic types. In the periphery, preganglionic fibers leave the CNS and synapse on postganglionic neurons in the sympathetic chain or in sympathetic ganglia.\\n\\n\\n\\n\\nThe smaller fibers are affected first in DM. With continued exposure to hyperglycemia, the larger fibers become affected. Fibers of different size mediate different types of sensation, as shown in the table below.\\n\\n\\n\\n\\n\\n\\n\\n\\nTable. Subdivisions of Sensory Neurons\\n (Open Table in a new window)\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nFiber Type \\n\\n\\nSize \\n\\n\\nModality \\n\\n\\nMyelination \\n\\n\\n\\n\\n\\n\\nA-alpha (I)\\n\\n\\n13-20 micrometers\\n\\n\\nLimb proprioception\\n\\n\\nYes\\n\\n\\n\\n\\n\\n\\nA-beta (II)\\n\\n\\n6-12 micrometers\\n\\n\\nLimb proprioception, vibration, pressure\\n\\n\\nYes\\n\\n\\n\\n\\n\\n\\nA-delta (III)\\n\\n\\n1-5 micrometers\\n\\n\\nMechanical sharp pain\\n\\n\\nYes\\n\\n\\n\\n\\n\\n\\nC (IV)\\n\\n\\n0.2-1.5 micrometers\\n\\n\\nThermal pain, mechanical burning pain\\n\\n\\nNo\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n         Previous\\n        \\n\\n\\n\\n         Next: \\n        \\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nPathophysiology\\n\\n\\n\\n\\n\\n\\nThe factors leading to the development of diabetic neuropathy are not understood completely, and multiple hypotheses have been advanced.\\n\\n\\n [\\n7\\n, \\n8\\n, \\n9\\n, \\n10\\n, \\n11\\n, \\n12\\n, \\n13\\n, \\n14\\n, \\n15\\n, \\n16\\n] \\nIt is generally accepted to be a multifactorial process. Development of symptoms depends on many factors, such as total hyperglycemic exposure and other risk factors such as elevated lipids, blood pressure, smoking, increased height, and high exposure to other potentially neurotoxic agents such as ethanol. Genetic factors may also play a role.\\n\\n\\n [\\n17\\n] \\nImportant contributing biochemical mechanisms in the development of the more common symmetrical forms of diabetic polyneuropathy likely include the polyol pathway, advanced glycation end products, and oxidative stress.\\n\\n\\n\\n\\nFor more information, see \\nType 2 Diabetes and TCF7L2\\n.\\n\\n\\n\\n\\nPolyol pathway\\n\\n\\nHyperglycemia causes increased levels of intracellular glucose in nerves, leading to saturation of the normal glycolytic pathway. Extra glucose is shunted into the polyol pathway and converted to sorbitol and fructose by the enzymes aldose reductase and sorbitol dehydrogenase.\\n\\n\\n [\\n18\\n] \\nAccumulation of sorbitol and fructose lead to reduced nerve myoinositol, decreased membrane Na\\n+\\n/K\\n+\\n -ATPase activity, impaired axonal transport, and structural breakdown of nerves, causing abnormal action potential propagation. This is the rationale for the use of aldose reductase inhibitors to improve nerve conduction.\\n\\n\\n [\\n19\\n] \\n\\n\\n\\n\\nAdvanced glycation end products\\n\\n\\nThe nonenzymatic reaction of excess glucose with proteins, nucleotides, and lipids results in advanced glycation end products (AGEs) that may have a role in disrupting neuronal integrity and repair mechanisms through interference with nerve cell metabolism and axonal transport.\\n\\n\\n [\\n20\\n] \\n\\n\\n\\n\\nOxidative stress\\n\\n\\nThe increased production of free radicals in diabetes may be detrimental via several mechanisms that are not fully understood. These include direct damage to blood vessels leading to nerve ischemia and facilitation of AGE reactions. Despite the incomplete understanding of these processes, use of the antioxidant alpha-lipoic acid may hold promise for improving neuropathic symptoms.\\n\\n\\n [\\n21\\n, \\n22\\n, \\n23\\n] \\n\\n\\n\\n\\nRelated contributing factors\\n\\n\\nProblems that are a consequence of or co-contributors to these disturbed biochemical processes include altered gene expression with altered cellular phenotypes, changes in cell physiology relating to endoskeletal structure or cellular transport, reduction in neurotrophins, and nerve ischemia.\\n\\n\\n [\\n24\\n] \\nClinical trials of the best-studied neurotrophin, human recombinant nerve growth factor, were disappointing. With future refinements, however, pharmacologic intervention targeting one or more of these mechanisms may prove successful.\\n\\n\\n\\n\\nIn the case of focal or asymmetrical diabetic neuropathy syndromes, vascular injury or autoimmunity may play more important roles.\\n\\n\\n [\\n25\\n] \\n\\n\\n\\n\\nA cross-sectional, case-control study by Gastoł et al indicated that in patients with type 1 diabetes mellitus (DM), epigenetic factors are involved in the development of autonomic neuropathy. T1DM patients with autonomic neuropathy showed differences in gene methylation compared with T1DM patients without neuropathy. For example, in the \\nNINJ2\\n gene, which is involved in nerve regeneration, patients with autonomic neuropathy had significantly greater methylation in the first axon than did the other patients with type 1. In addition, two genes involved in nerve functionality, \\nBRSK2\\n and \\nCLDN4\\n, showed decreased methylation (in the region of the first intron of \\nBRSK2\\n and the 5’UTR regions of \\nCLDN4\\n) in the patients with neuropathy.\\n\\n\\n [\\n26\\n] \\n\\n\\n\\n\\nA study by Groener et al of sciatic nerve lesions in diabetic polyneuropathy indicated that lesion load positively correlates with the duration of diabetes, attaining clinical relevance “once a critical amount of nerve fascicles is affected.”\\n\\n\\n [\\n27\\n] \\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n         Previous\\n        \\n\\n\\n\\n         Next: \\n        \\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nEtiology\\n\\n\\n\\n\\n\\n\\nRisk factors that are associated with more severe symptoms include the following\\n\\n\\n [\\n28\\n] \\n:\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nPoor glycemic control\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nAdvanced age\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nHypertension\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nLong duration of DM\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nDyslipidemia\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nSmoking\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nHeavy alcohol intake\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nHLA-DR3/4 phenotype\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nTall height\\n\\n\\n\\n\\n\\n\\n\\n\\nDevelopment of symptoms depends on many factors, such as total hyperglycemic exposure and other risk factors such as elevated lipids, blood pressure, smoking, increased height, and high exposure to other potentially neurotoxic agents such as ethanol. Genetic factors may also play a role.\\n\\n\\n [\\n17\\n] \\n\\n\\n\\n\\nPeripheral neuropathies have been described in patients with primary DM (types 1 and 2) and in those with secondary diabetes of diverse causes, suggesting a common etiologic mechanism based on chronic hyperglycemia. The contribution of hyperglycemia has received strong support from the Diabetes Control and Complications Trial (DCCT).\\n\\n\\n [\\n29\\n] \\n\\n\\n\\n\\nAn association between impaired glucose tolerance and peripheral neuropathy has been construed as further evidence of a dose-dependent effect of hyperglycemia on nerves, although this relationship remains an area of some controversy for type 2 diabetes and prediabetes.\\n\\n\\n [\\n30\\n, \\n31\\n, \\n32\\n, \\n33\\n] \\n\\n\\n\\n\\nA study by Jende et al indicated that in patients with type 1 diabetes, the predominant nerve lesions of distal symmetrical diabetic neuropathy develop in relation to poor glycemic control and nerve conduction loss, while in type 2 diabetes, these lesions arise in association with lipid metabolism changes.\\n\\n\\n [\\n34\\n] \\n\\n\\n\\n\\nA study by Pai et al indicated that in adults with type 2 diabetes, an association exists between variability in fasting plasma glucose and the risk for painful diabetic peripheral neuropathy. Using the coefficient of variation (CV) for fasting plasma glucose, the investigators found that, after consideration of HbA1c, the odds ratios for the development of painful diabetic peripheral neuropathy were 4.08 and 5.49 for the third and fourth CV quartiles, respectively, compared with the first quartile.\\n\\n\\n [\\n35\\n] \\n\\n\\n\\n\\nA study by Altaf et al indicated that obstructive sleep apnea (OSA) is linked to small-fiber neuropathy in type 2 diabetes, with poly–adenosine diphosphate ribose polymerase activation being a possible mechanism behind OSA’s association with diabetic peripheral neuropathy and endothelial dysfunction.\\n\\n\\n [\\n36\\n] \\n\\n\\n\\n\\nA study by Dabelea et al found that among teenagers and young adults who had been diagnosed with type 1 or type 2 diabetes during childhood or adolescence, the age-adjusted prevalence of peripheral neuropathy was greater in those with type 2 diabetes than in patients with type 1 diabetes (17.7% vs 8.5%, respectively). After modifications had been made for established risk factors measured over time, the odds ratio for peripheral neuropathy in patients with type 2 diabetes versus those with type 1 was 2.52.\\n\\n\\n [\\n37\\n] \\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n         Previous\\n        \\n\\n\\n\\n         Next: \\n        \\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nEpidemiology\\n\\n\\n\\n\\n\\n\\nUnited States statistics\\n\\n\\nA large American study estimated that 47% of patients with diabetes have some peripheral neuropathy.\\n\\n\\n [\\n38\\n] \\nNeuropathy is estimated to be present in 7.5% of patients at the time of diabetes diagnosis. More than half of cases are distal symmetric polyneuropathy. Focal syndromes such as carpal tunnel syndrome (14-30%),\\n\\n\\n [\\n39\\n, \\n40\\n, \\n41\\n] \\nradiculopathies/plexopathies, and cranial neuropathies account for the rest. Solid prevalence data for the latter 2 less-common syndromes is lacking.\\n\\n\\n\\n\\nThe wide variability in symmetric diabetic polyneuropathy prevalence data is due to lack of consistent criteria for diagnosis, variable methods of selecting patients for study, and differing assessment techniques. In addition, because many patients with diabetic polyneuropathy are initially asymptomatic, detection is extremely dependent on careful neurologic examination by the primary care clinician. The use of additional diagnostic techniques, such as autonomic or quantitative sensory testing, might result in a higher recorded prevalence.\\n\\n\\n [\\n42\\n, \\n43\\n] \\n\\n\\n\\n\\nInternational statistics\\n\\n\\nIn a cohort of 4400 Belgian patients, Pirart et al found that 7.5% of patients already had neuropathy when diagnosed with diabetes.\\n\\n\\n [\\n44\\n] \\nAfter 25 years, the number with neuropathy rose to 45%. In the United Kingdom, the prevalence of diabetic neuropathy among the hospital clinic population was noted to be around 29%.\\n\\n\\n [\\n45\\n] \\n\\xa0A study by Pan et al found that in Beijing, peripheral neuropathy had prevalence rates of 21.92% and 35.34% in patients with type 1 and type 2 diabetes, respectively.\\n\\n\\n [\\n46\\n] \\n\\n\\n\\n\\nA Korean study, by Moon et al, looked at changes over a 10-year period in the prevalence of diabetic neuropathy among people with diabetes aged 30 years or older. The investigators found that the annual prevalence rose from 24.9% in 2006 to 26.6% in 2007. The value then gradually fell, declining to 20.8% in 2015. The prevalence was 3-4% greater in women than men throughout the study period.\\n\\n\\n [\\n47\\n] \\n\\n\\n\\n\\nDiabetic neuropathy in racial minorities\\n\\n\\nNo definite racial predilection has been demonstrated for diabetic neuropathy. However, members of minority groups (eg, Hispanics, African Americans) have more secondary complications from diabetic neuropathy, such as lower-extremity amputations, than whites.\\n\\n\\n [\\n28\\n] \\nThey also have more hospitalizations for neuropathic complications.\\n\\n\\n\\n\\nSex differences in diabetic neuropathy\\n\\n\\nDM affects men and women with equal frequency. However, male patients with type 2 diabetes may develop diabetic polyneuropathy earlier than female patients,\\n\\n\\n [\\n48\\n] \\nand neuropathic pain causes more morbidity in females than in males.\\n\\n\\n\\n\\nDiabetic neuropathy and advancing age\\n\\n\\nDiabetic neuropathy can occur at any age but is more common with increasing age and severity and duration of diabetes.\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n         Previous\\n        \\n\\n\\n\\n         Next: \\n        \\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nPrognosis\\n\\n\\n\\n\\n\\n\\nPatients with untreated or inadequately treated diabetes have higher morbidity and complication rates related to neuropathy than patients with tightly controlled diabetes. Repetitive trauma to affected areas may cause skin breakdown, progressive ulceration, and infection. Amputations and death may result.\\n\\n\\n\\n\\nTreating diabetic neuropathy is a difficult task for the physician and patient. Most of the medicines mentioned in the Medication section do not lead to complete symptom relief. Clinical trials are under way to help find new ways to treat symptoms and delay disease progression.\\n\\n\\n\\n\\nMortality is higher in people with cardiovascular autonomic neuropathy (CAN). The overall mortality rate over periods up to 10 years was 27% in patients with DM and CAN detected, compared with a 5% mortality rate in those without evidence of CAN. Morbidity results from \\nfoot ulceration\\n and lower-extremity amputation. These 2 complications are the most common causes of hospitalization among people with DM in Western countries. Severe pain, dizziness, diarrhea, and impotence are common symptoms that decrease the QOL of a patient with DM. In patients with diabetic peripheral neuropathy, the prognosis is good, but the patient\\'s QOL is reduced.\\n\\n\\n\\n\\nIn a Canadian study of patients with painful diabetic neuropathy being managed in a tertiary care setting, Mai et al found that at 12-month follow-up, significant improvement in pain and function had been achieved in almost one third of these individuals. That included pain reduction of 30% or greater in 37.2% of patients, functional improvement (reduction of 1 or greater on the Pain Interference Scale) in 51.2% of patients, and achievement of both of these measures in 30.2% of patients. Polypharmacy was found to be essential to symptom management and included the use of analgesic antidepressants and anticonvulsants.\\n\\n\\n [\\n49\\n] \\n\\n\\n\\n\\nFor more information, go to \\nDiabetic Foot\\n.\\n\\n\\n\\n\\nfor more information, go to \\nDiabetic Foot Infections\\n.\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n         Previous\\n        \\n\\n\\n\\n         Next: \\n        \\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nPatient Education\\n\\n\\n\\n\\n\\n\\nControlling diet and nutrition are paramount to improving the secondary complications of diabetes, including neuropathy. Patients with diabetic neuropathy should work with nutritionists or their primary care physicians to develop a realistic diet for lowering blood glucose and minimizing large fluctuations in blood glucose.\\n\\n\\n\\n\\nPatients with diabetic neuropathy should be encouraged to remain as active as possible. However, those with significant sensory loss or autonomic dysfunction should be cautioned about exercising in extreme weather conditions, which may result in injury. For example, patients with extremity numbness may not be aware of frostbite injuries during prolonged cold exposure, or those with abnormal sweating may become easily overheated in hot conditions. In most cases, consultation with the patient\\'s regular physician is reasonable before the initiation of a regular exercise program.\\n\\n\\n\\n\\nPatients with diabetic neuropathy need to be educated on all aspects of their condition, and they need to know that it is very much affected by poor glycemic control. Prevention of diabetic neuropathy is potentially best achieved by having near-euglycemic control from the onset of DM. Even in patients with symptoms of diabetic neuropathy, controlling blood glucose to euglycemic levels reduces pain significantly. When a person has poor control and becomes euglycemic quickly, pain may be exacerbated (possibly due to an insulin effect), but this pain disappears in a few days. The bottom line for patients is that medications are imperfect. Many result in no pain relief for certain patients. However, glucose control is something that the patient can achieve that may reduce pain.\\n\\n\\n\\n\\nThe importance of protection and care of insensitive feet cannot be overemphasized. Patients should be instructed to trim their toenails with great care and to be fastidious about foot hygiene. Any fungal or bacterial infection mandates prompt medical attention. The need for well-fitting shoes should be stressed.\\n\\n\\n\\n\\nDiabetic polyneuropathy is often associated with diabetic retinopathy and nephropathy. Patients with neuropathy should be counseled to seek appropriate eye care and discuss renal care and follow-up with their primary care physicians or endocrinologists.\\n\\n\\n\\n\\nPatient education should begin in the primary care office. The following outline reviews some common questions and answers that can serve as a springboard for discussion.\\n\\n\\n\\n\\nWhat is diabetic neuropathy?\\n\\n\\nDiabetic neuropathy is nerve damage caused by diabetes. In the United States, diabetes is one of the most common causes of nerve damage, also known as peripheral neuropathy. Diabetic neuropathy can affect nerves that supply feeling and movement in the arms and legs. It can also affect the nerves that regulate unconscious vital functions such as heart rate and digestion.\\n\\n\\n\\n\\nHow does diabetic neuropathy occur?\\n\\n\\nDoctors have been studying this problem for many years, but they do not yet understand exactly how diabetes damages nerves. However, they have observed that good control of blood sugar levels helps prevent diabetic neuropathy and slows its progression, especially in patients with type 1 diabetes.\\n\\n\\n\\n\\nWhat are the symptoms?\\n\\n\\nSymptoms of diabetic neuropathy may include the following:\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nNumbness or loss of feeling (usually in the feet and legs first, then the hands)\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nPain\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nMuscle weakness\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nLow blood pressure and dizziness when rising quickly from sitting or lying down\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nRapid or irregular heartbeats\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nTrouble having an erection\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nNausea or vomiting\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nDifficulty swallowing\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nConstipation or diarrhea\\n\\n\\n\\n\\n\\n\\n\\n\\nPain from diabetic neuropathy may range from minor discomfort or tingling in toes to severe pain. Pain may be sharp or lightning-like, deep and aching, or burning. Extreme sensitivity to the slightest touch can also occur (allodynia).\\n\\n\\n\\n\\nA study by D’Amato et al indicated that among diabetes-related complications and comorbidities, painful diabetic polyneuropathy is the greatest determinant of depression in patients with diabetes. The study involved 181 patients, including 25 with painful diabetic polyneuropathy and 46 with the painless form of the condition.\\n\\n\\n [\\n50\\n] \\n\\n\\n\\n\\nHow can I help prevent diabetic neuropathy?\\n\\n\\nThe following steps may help to prevent or slow the worsening of diabetic neuropathy\\n\\n\\n [\\n51\\n] \\n:\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nControl diabetes; try to keep blood sugar at a normal level\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nMaintain normal blood pressure\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nExercise regularly, according to the healthcare provider\\'s recommendation\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nStop smoking\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nLimit the amount of alcohol intake because excessive alcohol also can cause neuropathy or make it worse\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nEat a healthy diet and avoid elevated levels of triglycerides in the blood\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nMaintain a healthy weight\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nKeep follow-up appointments with the healthcare provider\\n\\n\\n\\n\\n\\n\\n\\n\\nHow is diabetic neuropathy treated?\\n\\n\\nNo treatment is currently available to reverse neuropathy. The best approach is to control the diabetes and other risk factors.\\n\\n\\n\\n\\nMuscle weakness is treated with support, such as braces. Physical therapy and regular exercise may help patients maintain the muscle strength they have.\\n\\n\\n\\n\\nPain medications may help make pain more tolerable. Medications can be used to treat nausea, vomiting, and diarrhea.\\n\\n\\n\\n\\nMen who have trouble having erections because of neuropathy should talk to their healthcare providers. Medications can help a man achieve and maintain an erection, or prosthetic devices can be put in the penis.\\n\\n\\n\\n\\nPreventing injuries such as burns, cuts, or broken bones is especially important, because patients with neuropathy have more complications from simple injuries and may not heal as quickly as healthy individuals.\\n\\n\\n\\n\\nHow can I take care of myself?\\n\\n\\nDiabetes patients can take the following self-care measures:\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nWork with primary care physicians and endocrinologists to control glucose levels\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nExamine the skin of feet and lower legs regularly to look for injuries\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nSee a healthcare provider promptly for calluses, sores on the skin, or other potential problems so they can be treated properly.\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nWear good-fitting, comfortable shoes that protect the feet\\n\\n\\n\\n\\n\\n\\n\\n\\nHow long will the problem last?\\n\\n\\nOnce a person has neuropathy, the symptoms will persist indefinitely, but most people with diabetic neuropathy are able to lead active, fulfilling lives. Keeping blood sugar under good control may stop neuropathy from worsening.\\n\\n\\n\\n\\nFor excellent patient education resources, visit eMedicineHealth\\'s \\nDiabetes Center\\n and \\nMen\\'s Health Center\\n. Also, see eMedicineHealth\\'s patient education articles, \\nDiabetes Mellitus\\n and \\nDiabetic Foot Care\\n.\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n         Previous\\n        \\n\\n\\n\\n\\n\\n\\n\\n\\nClinical Presentation\\n\\n\\n\\n\\n\\n        \\xa0\\n       \\n\\n\\n\\n\\n\\n\\n\\n      \\xa0\\n     \\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nReferences\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nZeng L, Alongkronrusmee D, van Rijn RM. An integrated perspective on diabetic, alcoholic, and drug-induced neuropathy, etiology, and treatment in the US. \\nJ Pain Res\\n. 2017 Jan 20. 10:219-228. \\n[QxMD MEDLINE Link]\\n. \\n[Full Text]\\n.\\n\\n\\nBodman MA, Varacallo M. Peripheral Diabetic Neuropathy. \\nStatPearls\\n. 2021 Jan. \\n[QxMD MEDLINE Link]\\n. \\n[Full Text]\\n.\\n\\n\\nCarmichael J, Fadavi H, Ishibashi F, Shore AC, Tavakoli M. Advances in Screening, Early Diagnosis and Accurate Staging of Diabetic Neuropathy. \\nFront Endocrinol (Lausanne)\\n. 2021. 12:671257. \\n[QxMD MEDLINE Link]\\n. \\n[Full Text]\\n.\\n\\n\\nSkyler JS. Diabetic complications. The importance of glucose control. \\nEndocrinol Metab Clin North Am\\n. 1996 Jun. 25(2):243-54. \\n[QxMD MEDLINE Link]\\n. \\n\\n\\nBoulton AJ, Malik RA. Diabetic neuropathy. \\nMed Clin North Am\\n. 1998 Jul. 82(4):909-29. \\n[QxMD MEDLINE Link]\\n. \\n\\n\\nJuster-Switlyk K, Smith AG. Updates in diabetic peripheral neuropathy. \\nF1000Res\\n. 2016. 5:\\n[QxMD MEDLINE Link]\\n. \\n[Full Text]\\n.\\n\\n\\nBromberg MB. Peripheral neurotoxic disorders. \\nNeurol Clin\\n. 2000 Aug. 18(3):681-94. \\n[QxMD MEDLINE Link]\\n. \\n\\n\\nGoetz CG, Pappert EJ. \\nTextbook of Clinical Neurology\\n. Philadelphia: WB Saunders Co; 1999. \\n\\n\\nPourmand R. Diabetic neuropathy. \\nNeurol Clin\\n. 1997 Aug. 15(3):569-76. \\n[QxMD MEDLINE Link]\\n. \\n\\n\\nSugimoto K, Murakawa Y, Sima AA. Diabetic neuropathy--a continuing enigma. \\nDiabetes Metab Res Rev\\n. 2000 Nov-Dec. 16(6):408-33. \\n[QxMD MEDLINE Link]\\n. \\n\\n\\nVinik AI, Park TS, Stansberry KB, Pittenger GL. Diabetic neuropathies. \\nDiabetologia\\n. 2000 Aug. 43(8):957-73. \\n[QxMD MEDLINE Link]\\n. \\n\\n\\nWilson JD. \\nWilliams Textbook of Endocrinology\\n. 9th ed. Philadelphia: WB Saunders Co; 1998. \\n\\n\\nZochodne DW. Diabetic polyneuropathy: an update. \\nCurr Opin Neurol\\n. 2008 Oct. 21(5):527-33. \\n[QxMD MEDLINE Link]\\n. \\n\\n\\nCalcutt NA, Dunn JS. \\nPain: Nociceptive and Neuropathic Mechanisms\\n. Anesthesiology Clinics of North America.; 1997. \\n\\n\\nMalik RA. Pathology and pathogenesis of diabetic neuropathy. \\nDiabetes Reviews\\n. 1999. 7:253-60. \\n\\n\\nShigeta H, Yamaguchi M, Nakano K, Obayashi H, Takemura R, Fukui M. Serum autoantibodies against sulfatide and phospholipid in NIDDM patients with diabetic neuropathy. \\nDiabetes Care\\n. 1997 Dec. 20(12):1896-9. \\n[QxMD MEDLINE Link]\\n. \\n\\n\\nTavakkoly-Bazzaz J, Amoli MM, Pravica V, Chandrasecaran R, Boulton AJ, Larijani B. VEGF gene polymorphism association with diabetic neuropathy. \\nMol Biol Rep\\n. 2010 Mar 30. \\n[QxMD MEDLINE Link]\\n. \\n\\n\\nCarrington AL, Litchfield JE. The aldose reductase pathway and nonenzymatic glycation in the pathogenesis of diabetic neuropathy: a critical review for the end of the 20th century. \\nDiabetes Reviews\\n. 1999. 7:275-99. \\n\\n\\nGreene DA, Arezzo JC, Brown MB. Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy. Zenarestat Study Group. \\nNeurology\\n. 1999 Aug 11. 53(3):580-91. \\n[QxMD MEDLINE Link]\\n. \\n\\n\\nRyle C, Donaghy M. Non-enzymatic glycation of peripheral nerve proteins in human diabetics. \\nJ Neurol Sci\\n. 1995 Mar. 129(1):62-8. \\n[QxMD MEDLINE Link]\\n. \\n\\n\\nZiegler D, Ametov A, Barinov A, Dyck PJ, Gurieva I, Low PA. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. \\nDiabetes Care\\n. 2006 Nov. 29(11):2365-70. \\n[QxMD MEDLINE Link]\\n. \\n\\n\\nFigueroa-Romero C, Sadidi M, Feldman EL. Mechanisms of disease: The oxidative stress theory of diabetic neuropathy. \\nRev Endocr Metab Disord\\n. 2008 Dec. 9(4):301-14. \\n[QxMD MEDLINE Link]\\n. \\n\\n\\nZiegler D, Reljanovic M, Mehnert H, Gries FA. Alpha-lipoic acid in the treatment of diabetic polyneuropathy in Germany: current evidence from clinical trials. \\nExp Clin Endocrinol Diabetes\\n. 1999. 107(7):421-30. \\n[QxMD MEDLINE Link]\\n. \\n\\n\\nApfel SC, Kessler JA, Adornato BT, et al. Recombinant human nerve growth factor in the treatment of diabetic polyneuropathy. NGF Study Group. \\nNeurology\\n. 1998 Sep. 51(3):695-702. \\n[QxMD MEDLINE Link]\\n. \\n\\n\\nKrendel DA, Zacharias A, Younger DS. Autoimmune diabetic neuropathy. \\nNeurol Clin\\n. 1997 Nov. 15(4):959-71. \\n[QxMD MEDLINE Link]\\n. \\n\\n\\nGastol J, Kapusta P, Polus A, et al. Epigenetic mechanism in search for the pathomechanism of diabetic neuropathy development in diabetes mellitus type 1 (T1DM). \\nEndocrine\\n. 2020 Jan 4. \\n[QxMD MEDLINE Link]\\n. \\n\\n\\nGroener JB, Jende JME, Kurz FT, et al. Understanding Diabetic Neuropathy: From Subclinical Nerve Lesions to Severe Nerve Fiber Deficits. A Cross-Sectional Study in Patients with Type 2 Diabetes and Healthy Controls. \\nDiabetes\\n. 2019 Dec 11. \\n[QxMD MEDLINE Link]\\n. \\n\\n\\nDorsey RR, Eberhardt MS, Gregg EW, Geiss LS. Control of risk factors among people with diagnosed diabetes, by lower extremity disease status. \\nPrev Chronic Dis\\n. 2009 Oct. 6(4):A114. \\n[QxMD MEDLINE Link]\\n. \\n[Full Text]\\n.\\n\\n\\nDiabetes control and complications trial research group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. \\nN Engl J Med\\n. 1993 Sep 30. 329(14):977-86. \\n[QxMD MEDLINE Link]\\n. \\n\\n\\nHarati Y. Diabetes and the nervous system. \\nEndocrinol Metab Clin North Am\\n. 1996 Jun. 25(2):325-59. \\n[QxMD MEDLINE Link]\\n. \\n\\n\\nRutkove SB. A 52-year-old woman with disabling peripheral neuropathy: review of diabetic polyneuropathy. \\nJAMA\\n. 2009 Oct 7. 302(13):1451-8. \\n[QxMD MEDLINE Link]\\n. \\n\\n\\nFinucane TE. Diabetic polyneuropathy and glucose control. \\nJAMA\\n. 2010 Feb 3. 303(5):420; author reply 420-1. \\n[QxMD MEDLINE Link]\\n. \\n\\n\\nBoulton AJ, Malik RA. Neuropathy of impaired glucose tolerance and its measurement. \\nDiabetes Care\\n. 2010 Jan. 33(1):207-9. \\n[QxMD MEDLINE Link]\\n. \\n[Full Text]\\n.\\n\\n\\nJende JME, Groener JB, Oikonomou D, et al. Diabetic neuropathy differs between type 1 and type 2 diabetes Insights from magnetic resonance neurography. \\nAnn Neurol\\n. 2018 Feb 14. \\n[QxMD MEDLINE Link]\\n. \\n\\n\\nPai YW, Lin CH, Lee IT, Chang MH. Variability of fasting plasma glucose and the risk of painful diabetic peripheral neuropathy in patients with type 2 diabetes. \\nDiabetes Metab\\n. 2018 Feb 4. \\n[QxMD MEDLINE Link]\\n. \\n\\n\\nAltaf QA, Ali A, Piya MK, Raymond NT, Tahrani AA. The relationship between obstructive sleep apnea and intra-epidermal nerve fiber density, PARP activation and foot ulceration in patients with type 2 diabetes. \\nJ Diabetes Complications\\n. 2016 Jun 2. \\n[QxMD MEDLINE Link]\\n. \\n\\n\\nDabelea D, Stafford JM, Mayer-Davis EJ, et al. Association of Type 1 Diabetes vs Type 2 Diabetes Diagnosed During Childhood and Adolescence With Complications During Teenage Years and Young Adulthood. \\nJAMA\\n. 2017 Feb 28. 317 (8):825-35. \\n[QxMD MEDLINE Link]\\n. \\n\\n\\nDyck PJ, Kratz KM, Karnes JL, Litchy WJ, Klein R, Pach JM, et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. \\nNeurology\\n. 1993 Apr. 43(4):817-24. \\n[QxMD MEDLINE Link]\\n. \\n\\n\\nPerkins BA, Olaleye D, Bril V. Carpal tunnel syndrome in patients with diabetic polyneuropathy. \\nDiabetes Care\\n. 2002 Mar. 25(3):565-9. \\n[QxMD MEDLINE Link]\\n. \\n\\n\\nShaw JE, Zimmet PZ. The epidemiology of diabetic neuropathy. \\nDiabetes Reviews\\n. 1999. 7:245-52. \\n\\n\\nSingh R, Gamble G, Cundy T. Lifetime risk of symptomatic carpal tunnel syndrome in Type 1 diabetes. \\nDiabet Med\\n. 2005 May. 22(5):625-30. \\n[QxMD MEDLINE Link]\\n. \\n\\n\\nGaler BS, Gianas A, Jensen MP. Painful diabetic polyneuropathy: epidemiology, pain description, and quality of life. \\nDiabetes Res Clin Pract\\n. 2000 Feb. 47(2):123-8. \\n[QxMD MEDLINE Link]\\n. \\n\\n\\nDyck PJ, O\\'Brien PC. Quantitative sensation testing in epidemiological and therapeutic studies of peripheral neuropathy. \\nMuscle Nerve\\n. 1999 Jun. 22(6):659-62. \\n[QxMD MEDLINE Link]\\n. \\n\\n\\nPirart J. Diabetes mellitus and its degenerative complication: a prospective study of 4,400 patient observed between 1947 and 1973. \\nDiabetes Care\\n. 1978. 1:168-188. \\n\\n\\nYoung MJ, Boulton AJ, MacLeod AF, Williams DR, Sonksen PH. A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. \\nDiabetologia\\n. 1993 Feb. 36(2):150-4. \\n[QxMD MEDLINE Link]\\n. \\n\\n\\nPan Q, Li Q, Deng W, et al. Prevalence of and Risk Factors for Peripheral Neuropathy in Chinese Patients With Diabetes: A Multicenter Cross-Sectional Study. \\nFront Endocrinol (Lausanne)\\n. 2018. 9:617. \\n[QxMD MEDLINE Link]\\n. \\n[Full Text]\\n.\\n\\n\\nMoon SS, Kim CH, Kang SM, et al. Status of Diabetic Neuropathy in Korea: A National Health Insurance Service-National Sample Cohort Analysis (2006 to 2015). \\nDiabetes Metab J\\n. 2021 Jan. 45 (1):115-9. \\n[QxMD MEDLINE Link]\\n. \\n[Full Text]\\n.\\n\\n\\nAaberg ML, Burch DM, Hud ZR, Zacharias MP. Gender differences in the onset of diabetic neuropathy. \\nJ Diabetes Complications\\n. 2008 Mar-Apr. 22(2):83-7. \\n[QxMD MEDLINE Link]\\n. \\n\\n\\nMai LM, Clark AJ, Gordon AS, et al. Long-Term Outcomes in the Management of Painful Diabetic Neuropathy. \\nCan J Neurol Sci\\n. 2017 Jan 9. 1-6. \\n[QxMD MEDLINE Link]\\n. \\n\\n\\nD\\'Amato C, Morganti R, Greco C, et al. Diabetic peripheral neuropathic pain is a stronger predictor of depression than other diabetic complications and comorbidities. \\nDiab Vasc Dis Res\\n. 2016 Jun 22. \\n[QxMD MEDLINE Link]\\n. \\n\\n\\nTesfaye S, Watt J, Benbow SJ, Pang KA, Miles J, MacFarlane IA. Electrical spinal-cord stimulation for painful diabetic peripheral neuropathy. \\nLancet\\n. 1996 Dec 21-28. 348(9043):1698-701. \\n[QxMD MEDLINE Link]\\n. \\n\\n\\nJohnson DA, Vinik AI. Gastrointestinal Disturbances. \\nTherapy for Diabetes Mellitus\\n. American Diabetes Association; 1998. \\n\\n\\nZiegler D. Cardiovascular autonomic neuropathy: clinical manifestations and measurement. \\nDiabetes Reviews\\n. 1999. 7:342-57. \\n\\n\\nMeijer JW, van Sonderen E, Blaauwwiekel EE, et al. Diabetic neuropathy examination: a hierarchical scoring system to diagnose distal polyneuropathy in diabetes. \\nDiabetes Care\\n. 2000 Jun. 23(6):750-3. \\n[QxMD MEDLINE Link]\\n. \\n\\n\\nHokkam EN. Assessment of risk factors in diabetic foot ulceration and their impact on the outcome of the disease. \\nPrim Care Diabetes\\n. 2009 Nov. 3(4):219-24. \\n[QxMD MEDLINE Link]\\n. \\n\\n\\nCoppini DV, Wellmer A, Weng C, Young PJ, Anand P, Sönksen PH. The natural history of diabetic peripheral neuropathy determined by a 12 year prospective study using vibration perception thresholds. \\nJ Clin Neurosci\\n. 2001 Nov. 8(6):520-4. \\n[QxMD MEDLINE Link]\\n. \\n\\n\\nPerkins BA, Olaleye D, Zinman B, Bril V. Simple screening tests for peripheral neuropathy in the diabetes clinic. \\nDiabetes Care\\n. 2001 Feb. 24(2):250-6. \\n[QxMD MEDLINE Link]\\n. \\n\\n\\nDyck PJ, Turner DW, Davies JL, O\\'Brien PC, Dyck PJ, Rask CA. Electronic case-report forms of symptoms and impairments of peripheral neuropathy. \\nCan J Neurol Sci\\n. 2002 Aug. 29(3):258-66. \\n[QxMD MEDLINE Link]\\n. \\n\\n\\nBiaggioni I. Postural hypotension. \\nTherapy for Diabetes Mellitus\\n. American Diabetes Association; 1998. 423-30. \\n\\n\\nAyad H. Diabetic neuropathy: classification, clinical manifestations, diagnosis and management. Baba S et al, eds. \\nDiabetes Mellitus in Asia\\n. Amsterdam: Excerpta Medica; 1977. 222-4. \\n\\n\\nThomas PK. Classification, differential diagnosis, and staging of diabetic peripheral neuropathy. \\nDiabetes\\n. 1997 Sep. 46 Suppl 2:S54-7. \\n[QxMD MEDLINE Link]\\n. \\n\\n\\nAll About Diabetes. Date Accessed: October 30, 2008. \\nAmerican Diabetes Association\\n. \\n[Full Text]\\n.\\n\\n\\nDefinition and diagnosis of diabetes mellitus and intermediate hyperglycemia: A report of the World Health Organization and International Diabetes Federation\\n. Geneva, Switzerland: WHO Press; 2006. \\n\\n\\nAbbott CA, Vileikyte L, Williamson S, et al. Multicenter study of the incidence of and predictive risk factors for diabetic neuropathic foot ulceration. \\nDiabetes Care\\n. 1998 Jul. 21(7):1071-5. \\n[QxMD MEDLINE Link]\\n. \\n\\n\\nLlewelyn JG, Tomlinson DR, Thomas PK. Dyck PJ and Thomas PK. \\nDiabetic Neuropathies in Peripheral Neuropathy\\n. Philadelphia: Elsevier Saunders; 2005. 1951-91. \\n\\n\\nLozeron P, Nahum L, Lacroix C, Ropert A, Guglielmi JM, Said G. Symptomatic diabetic and non-diabetic neuropathies in a series of 100 diabetic patients. \\nJ Neurol\\n. 2002 May. 249(5):569-75. \\n[QxMD MEDLINE Link]\\n. \\n\\n\\nWaldman SD. Diabetic neuropathy: diagnosis and treatment for the pain management specialist. \\nCurr Rev Pain\\n. 2000. 4(5):383-7. \\n[QxMD MEDLINE Link]\\n. \\n\\n\\nDavidson MB. \\nDiabetes Mellitus: Diagnosis and Treatment\\n. 4th Ed. 1998. 297-307. \\n\\n\\nVinik AI. \\nNew Methods to Assess Diabetic Neuropathy for Clinical Research.60th Scientific Sessions of the American Diabetes Association\\n. American Diabetes Association; 2000. \\n\\n\\nBusko M. Common Tests May Miss Pediatric Diabetic Neuropathy. \\nMedscape Medical News\\n. Apr 11 2014. \\n[Full Text]\\n.\\n\\n\\nHirschfeld G, von Glischinski M, Blankenburg M, et al. Screening for peripheral neuropathies in children with diabetes: a systematic review. \\nPediatrics\\n. 2014 Apr 7. \\n[QxMD MEDLINE Link]\\n. \\n\\n\\nWalter-Holiner I, Barbarini DS, Lutschg J, et al. High Prevalence and Incidence of Diabetic Peripheral Neuropathy in Children and Adolescents With Type 1 Diabetes Mellitus: Results From a Five-Year Prospective Cohort Study. \\nPediatr Neurol\\n. 2017 Dec 13. \\n[QxMD MEDLINE Link]\\n. \\n\\n\\nTkac I, Bril V. Glycemic control is related to the electrophysiologic severity of diabetic peripheral sensorimotor polyneuropathy. \\nDiabetes Care\\n. 1998 Oct. 21(10):1749-52. \\n[QxMD MEDLINE Link]\\n. \\n\\n\\nBril V. Electrophysiologic testing. Gries FA, Cameron NE, Low PA, Ziegler D. \\nTextbook of Diabetic Neuropathy\\n. Stuttgart, Germany: Thieme Medical Publishers; 2003. 177-84. \\n\\n\\nHuang CC, Chen TW, Weng MC, Lee CL, Tseng HC, Huang MH. Effect of glycemic control on electrophysiologic changes of diabetic neuropathy in type 2 diabetic patients. \\nKaohsiung J Med Sci\\n. 2005 Jan. 21(1):15-21. \\n[QxMD MEDLINE Link]\\n. \\n\\n\\nSmith AG, Russell J, Feldman EL, et al. Lifestyle intervention for pre-diabetic neuropathy. \\nDiabetes Care\\n. 2006 Jun. 29(6):1294-9. \\n[QxMD MEDLINE Link]\\n. \\n\\n\\nApfel SC. Neurotrophic factors in the therapy of diabetic neuropathy. \\nAm J Med\\n. 1999 Aug 30. 107(2B):34S-42S. \\n[QxMD MEDLINE Link]\\n. \\n\\n\\nApfel SC. Diabetic Polyneuropathy. \\nDiabetes and Endocrinology Clinical Management\\n. 1999. \\n\\n\\nArgoff CE, Backonja MM, Belgrade MJ, Bennett GJ, Clark MR, Cole BE, et al. Consensus guidelines: treatment planning and options. Diabetic peripheral neuropathic pain. \\nMayo Clin Proc\\n. 2006 Apr. 81(4 Suppl):S12-25. \\n[QxMD MEDLINE Link]\\n. \\n\\n\\nBoulton A. Current and Emerging Treatments for Diabetic Neuropathies. \\nDiabetes Reviews\\n. 7:379-86. \\n\\n\\nSlovenkai MP. Foot problems in diabetes. \\nMed Clin North Am\\n. 1998 Jul. 82(4):949-71. \\n[QxMD MEDLINE Link]\\n. \\n\\n\\nO\\'Brien SP, Schwedler M, Kerstein MD. Peripheral neuropathies in diabetes. \\nSurg Clin North Am\\n. 1998 Jun. 78(3):393-408. \\n[QxMD MEDLINE Link]\\n. \\n\\n\\nMartin CL, Albers J, Herman WH, et al. Neuropathy among the diabetes control and complications trial cohort 8 years after trial completion. \\nDiabetes Care\\n. 2006 Feb. 29(2):340-4. \\n[QxMD MEDLINE Link]\\n. \\n\\n\\nSumner CJ, Sheth S, Griffin JW, et al. The spectrum of neuropathy in diabetes and impaired glucose tolerance. \\nNeurology\\n. 2003 Jan 14. 60(1):108-11. \\n[QxMD MEDLINE Link]\\n. \\n\\n\\nCallaghan BC, Little AA, Feldman EL, Hughes RA. Enhanced glucose control for preventing and treating diabetic neuropathy. \\nCochrane Database Syst Rev\\n. 2012 Jun 13. 6:CD007543. \\n[QxMD MEDLINE Link]\\n. \\n\\n\\nMoore RA, Wiffen PJ, Derry S, McQuay HJ. Gabapentin for chronic neuropathic pain and fibromyalgia in adults. \\nCochrane Database Syst Rev\\n. 2011 Mar 16. CD007938. \\n[QxMD MEDLINE Link]\\n. \\n\\n\\nZiegler D. Treatment of diabetic neuropathy and neuropathic pain: how far have we come?. \\nDiabetes Care\\n. 2008 Feb. 31 Suppl 2:S255-61. \\n[QxMD MEDLINE Link]\\n. \\n\\n\\nLunn MP, Hughes RA, Wiffen PJ. Duloxetine for treating painful neuropathy or chronic pain. \\nCochrane Database Syst Rev\\n. 2009. (4):CD007115. \\n[QxMD MEDLINE Link]\\n. \\n\\n\\nChou R, Carson S, Chan BK. Gabapentin versus tricyclic antidepressants for diabetic neuropathy and post-herpetic neuralgia: discrepancies between direct and indirect meta-analyses of randomized controlled trials. \\nJ Gen Intern Med\\n. 2009 Feb. 24(2):178-88. \\n[QxMD MEDLINE Link]\\n. \\n\\n\\nHayee MA, Mohammad QD, Haque A. Diabetic neuropathy and zinc therapy. \\nBangladesh Med Res Counc Bull\\n. 2005 Aug. 31(2):62-7. \\n[QxMD MEDLINE Link]\\n. \\n\\n\\nKawai T, Takei I, Tokui M, Funae O, Miyamoto K, Tabata M, et al. Effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy in patients with type 2 diabetes, in relation to suppression of N(varepsilon)-carboxymethyl lysine. \\nJ Diabetes Complications\\n. 2009 Aug 26. \\n[QxMD MEDLINE Link]\\n. \\n\\n\\nSchemmel KE, Padiyara RS, D\\'Souza JJ. Aldose reductase inhibitors in the treatment of diabetic peripheral neuropathy: a review. \\nJ Diabetes Complications\\n. 2009 Sep 10. \\n[QxMD MEDLINE Link]\\n. \\n\\n\\nHotta N, Akanuma Y, Kawamori R, Matsuoka K, Oka Y, Shichiri M, et al. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: the 3-year, multicenter, comparative Aldose Reductase Inhibitor-Diabetes Complications Trial. \\nDiabetes Care\\n. 2006 Jul. 29(7):1538-44. \\n[QxMD MEDLINE Link]\\n. \\n\\n\\nAndo H, Takamura T, Nagai Y, Kaneko S,. Erythrocyte sorbitol level as a predictor of the efficacy of epalrestat treatment for diabetic peripheral polyneuropathy. \\nJ Diabetes Complications\\n. 2006 Nov-Dec. 20(6):367-70. \\n[QxMD MEDLINE Link]\\n. \\n\\n\\nTesfaye S, Chaturvedi N, Eaton SE, Ward JD, Manes C, Ionescu-Tirgoviste C, et al. Vascular risk factors and diabetic neuropathy. \\nN Engl J Med\\n. 2005 Jan 27. 352(4):341-50. \\n[QxMD MEDLINE Link]\\n. \\n\\n\\nPetersen EA, Stauss TG, Scowcroft JA, et al. Effect of High-frequency (10-kHz) Spinal Cord Stimulation in Patients With Painful Diabetic Neuropathy: A Randomized Clinical Trial. \\nJAMA Neurol\\n. 2021 Jun 1. 78 (6):687-98. \\n[QxMD MEDLINE Link]\\n. \\n[Full Text]\\n.\\n\\n\\nDaousi C, Benbow SJ, MacFarlane IA. Electrical spinal cord stimulation in the long-term treatment of chronic painful diabetic neuropathy. \\nDiabet Med\\n. 2005 Apr. 22(4):393-8. \\n[QxMD MEDLINE Link]\\n. \\n\\n\\nAhn AC, Bennani T, Freeman R, Hamdy O, Kaptchuk TJ. Two styles of acupuncture for treating painful diabetic neuropathy--a pilot randomised control trial. \\nAcupunct Med\\n. 2007 Jun. 25(1-2):11-7. \\n[QxMD MEDLINE Link]\\n. \\n\\n\\nMiller RD. \\nAnesthesia\\n. 5th ed. New York: Churchill Livingstone; 2000. \\n\\n\\nFerreira MC, Carvalho VF, Kamamoto F, Tuma P Jr, Paggiaro AO. Negative pressure therapy (vacuum) for wound bed preparation among diabetic patients: case series. \\nSao Paulo Med J\\n. 2009. 127(3):166-70. \\n[QxMD MEDLINE Link]\\n. \\n\\n\\nCrouch J. Charcot\\'s joint and bilateral foot neuropathy. \\nAdv Nurse Pract\\n. 2005 Mar. 13(3):18. \\n[QxMD MEDLINE Link]\\n. \\n\\n\\nPfeiffer MA, Schumer M. Painful or insensitive lower extremity. \\nTherapy for Diabetes Mellitus\\n. American Diabetes Association; 1998. \\n\\n\\nJohnson CE, Takemoto JK. A Review of Beneficial Low-Intensity Exercises in Diabetic Peripheral Neuropathy Patients. \\nJ Pharm Pharm Sci\\n. 2019. 22 (1):22-7. \\n[QxMD MEDLINE Link]\\n. \\n[Full Text]\\n.\\n\\n\\n[Guideline] Colberg SR, Sigal RJ, Yardley JE, et al. Physical Activity/Exercise and Diabetes: A Position Statement of the American Diabetes Association. \\nDiabetes Care\\n. 2016 Nov. 39 (11):2065-79. \\n[QxMD MEDLINE Link]\\n. \\n[Full Text]\\n.\\n\\n\\nSomers DL, Somers MF. Treatment of neuropathic pain in a patient with diabetic neuropathy using transcutaneous electrical nerve stimulation applied to the skin of the lumbar region. \\nPhys Ther\\n. 1999 Aug. 79(8):767-75. \\n[QxMD MEDLINE Link]\\n. \\n\\n\\n[Guideline] Bril V, England J, Franklin GM, et al. Evidence-based guideline: Treatment of painful diabetic neuropathy: Report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology. Prepublished online April 11, 2011. \\n[Full Text]\\n.\\n\\n\\nTavakoli M, Kallinikos P, Iqbal A, et al. Corneal confocal microscopy detects improvement in corneal nerve morphology with an improvement in risk factors for diabetic neuropathy. \\nDiabet Med\\n. 2011 Oct. 28(10):1261-7. \\n[QxMD MEDLINE Link]\\n. \\n[Full Text]\\n.\\n\\n\\nPossidente CJ, Tandan R. A survey of treatment practices in diabetic peripheral neuropathy. \\nPrim Care Diabetes\\n. 2009 Nov. 3(4):253-7. \\n[QxMD MEDLINE Link]\\n. \\n\\n\\nBackonja M, Beydoun A, Edwards KR, Schwartz SL, Fonseca V, Hes M, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. \\nJAMA\\n. 1998 Dec 2. 280(21):1831-6. \\n[QxMD MEDLINE Link]\\n. \\n\\n\\nBennett GJ, Dworkin RH, Nicholson B. Anticonvulsant Therapy in the Treatment of Neuropathic Pain. \\nNeurology Treatment Update\\n. 2000. \\n\\n\\nBomholt SF, Mikkelsen JD, Blackburn-Munro G. Antinociceptive effects of the antidepressants amitriptyline, duloxetine, mirtazapine and citalopram in animal models of acute, persistent and neuropathic pain. \\nNeuropharmacology\\n. 2005 Feb. 48(2):252-63. \\n[QxMD MEDLINE Link]\\n. \\n\\n\\nZiegler D, Movsesyan L, Mankovsky B, Gurieva I, Abylaiuly Z, Strokov I. Treatment of symptomatic polyneuropathy with actovegin in type 2 diabetic patients. \\nDiabetes Care\\n. 2009 Aug. 32(8):1479-84. \\n[QxMD MEDLINE Link]\\n. \\n[Full Text]\\n.\\n\\n\\nLesser H, Sharma U, LaMoreaux L, Poole RM. Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial. \\nNeurology\\n. 2004 Dec 14. 63(11):2104-10. \\n[QxMD MEDLINE Link]\\n. \\n\\n\\nHuffman CL, Goldenberg JN, Weintraub J, et al. Efficacy and Safety of Once-Daily Controlled-Release Pregabalin for the Treatment of Patients With Postherpetic Neuralgia: A Double-Blind, Enriched Enrollment Randomized Withdrawal, Placebo-Controlled Trial. \\nClin J Pain\\n. 2017 Jul. 33 (7):569-78. \\n[QxMD MEDLINE Link]\\n. \\n\\n\\nBril V, England J, Franklin GM, Backonja M, Cohen J, Del Toro D, et al. Evidence-based guideline: Treatment of painful diabetic neuropathy: Report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. \\nNeurology\\n. 2011 Apr 11. \\n[QxMD MEDLINE Link]\\n. \\n\\n\\nWiffen PJ, Derry S, Moore RA, McQuay HJ. Carbamazepine for acute and chronic pain in adults. \\nCochrane Database Syst Rev\\n. 2011 Jan 19. CD005451. \\n[QxMD MEDLINE Link]\\n. \\n\\n\\nFDA Requires Boxed Warning and Risk Mitigation Strategy for Metoclopramide-Containing Drugs. U.S. Food and Drug Administration. Available at \\nhttp://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm149533.htm\\n. Accessed: May 16, 2000.\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n       Media Gallery\\n       \\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n of \\n         \\n0\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nTables\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nTable. Subdivisions of Sensory Neurons\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n           Table. Subdivisions of Sensory Neurons\\n          \\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nFiber Type \\n\\n\\nSize \\n\\n\\nModality \\n\\n\\nMyelination \\n\\n\\n\\n\\n\\n\\nA-alpha (I)\\n\\n\\n13-20 micrometers\\n\\n\\nLimb proprioception\\n\\n\\nYes\\n\\n\\n\\n\\n\\n\\nA-beta (II)\\n\\n\\n6-12 micrometers\\n\\n\\nLimb proprioception, vibration, pressure\\n\\n\\nYes\\n\\n\\n\\n\\n\\n\\nA-delta (III)\\n\\n\\n1-5 micrometers\\n\\n\\nMechanical sharp pain\\n\\n\\nYes\\n\\n\\n\\n\\n\\n\\nC (IV)\\n\\n\\n0.2-1.5 micrometers\\n\\n\\nThermal pain, mechanical burning pain\\n\\n\\nNo\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nBack to List\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nContributor Information and Disclosures \\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n        Author\\n       \\n\\n\\nDianna Quan, MD\\n Professor of Neurology, Director of Electromyography Laboratory, University of Colorado School of Medicine\\n\\n\\nDianna Quan, MD is a member of the following medical societies: \\nAmerican Academy of Neurology\\n, \\nAmerican Association of Neuromuscular and Electrodiagnostic Medicine\\n, \\nAmerican Neurological Association\\nDisclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: American Association of Neuromuscular and Electrodiagnostic Medicine; American Neuromuscular Foundation<br/>Serve(d) as a speaker or a member of a speakers bureau for: Alnylam<br/>Received research grant from: Alnylam; Pfizer; Ionis; Cytokinetics; Momenta/Janssen; Viela Bio; Avidity bioscience.\\n\\n\\n\\n\\n\\n        Coauthor(s)\\n       \\n\\n\\nHelen C Lin, MD\\n Assistant Professor of Neurology, Medical College of Wisconsin\\n\\n\\nHelen C Lin, MD is a member of the following medical societies: \\nAmerican Academy of Neurology\\n, \\nAmerican Association of Neuromuscular and Electrodiagnostic Medicine\\nDisclosure: Nothing to disclose.\\n\\n\\n\\n\\n\\n        Chief Editor\\n       \\n\\n\\nRomesh Khardori, MD, PhD, FACP\\n (Retired) Professor, Division of Endocrinology, Diabetes and Metabolism, Department of Internal Medicine, Eastern Virginia Medical School\\n\\n\\nRomesh Khardori, MD, PhD, FACP is a member of the following medical societies: \\nAmerican Association of Clinical Endocrinologists\\n, \\nAmerican College of Physicians\\n, \\nAmerican Diabetes Association\\n, \\nEndocrine Society\\nDisclosure: Nothing to disclose.\\n\\n\\n\\n        Acknowledgements\\n       \\n\\n\\nNeil A Busis, MD\\n Chief, Division of Neurology, Department of Medicine, Head, Clinical Neurophysiology Laboratory, University of Pittsburgh Medical Center-Shadyside\\n\\n\\nNeil A Busis, MD is a member of the following medical societies: \\nAmerican Academy of Neurology\\n and \\nAmerican Association of Neuromuscular and Electrodiagnostic Medicine\\n\\n\\nDisclosure: Nothing to disclose.\\n\\n\\nMilind J Kothari, DO\\n Professor and Vice-Chair, Department of Neurology, Pennsylvania State University College of Medicine; Consulting Staff, Department of Neurology, Penn State Milton S Hershey Medical Center\\n\\n\\nMilind J Kothari, DO is a member of the following medical societies: \\nAmerican Academy of Neurology\\n, \\nAmerican Association of Neuromuscular and Electrodiagnostic Medicine\\n, and \\nAmerican Neurological Association\\n\\n\\nDisclosure: Nothing to disclose. \\n\\n\\nFrancisco Talavera, PharmD, PhD\\n Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference\\n\\n\\nDisclosure: Medscape Salary Employment \\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nClose\\n\\n\\n\\n\\nWhat would you like to print?\\n\\n\\n\\n\\n\\n\\nWhat would you like to print?\\n\\n\\n\\n\\nPrint this section\\n\\n\\nPrint the entire contents of \\n\\n\\nPrint the entire contents of article\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n        Sections \\n        \\nDiabetic Neuropathy\\n\\n\\n\\n\\nOverview\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nPractice Essentials\\n\\n\\nBackground\\n\\n\\nAnatomy\\n\\n\\nPathophysiology\\n\\n\\nEtiology\\n\\n\\nEpidemiology\\n\\n\\nPrognosis\\n\\n\\nPatient Education\\n\\n\\nShow All\\n\\n\\n\\n\\nPresentation\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nHistory\\n\\n\\nPhysical Examination\\n\\n\\nClassification of Diabetic Neuropathy\\n\\n\\nStaging\\n\\n\\nShow All\\n\\n\\n\\n\\n\\n\\nDDx\\n\\n\\nWorkup\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nApproach Considerations\\n\\n\\nHemoglobin A1c and Fasting Plasma Glucose\\n\\n\\nBasic Laboratory Screening Tests\\n\\n\\nElectromyography and Nerve Conduction Studies\\n\\n\\nElectrophysiologic Studies\\n\\n\\nMRI and CT\\n\\n\\nNuclear Imaging\\n\\n\\nDoppler Imaging\\n\\n\\nMicrodialysis\\n\\n\\nElectrocardiography\\n\\n\\nNerve and Skin Biopsy\\n\\n\\nFuture Approaches\\n\\n\\nShow All\\n\\n\\n\\n\\nTreatment\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nApproach Considerations\\n\\n\\nGlycemic Control\\n\\n\\nDiabetic Neuropathic Pain Management\\n\\n\\nPain Control in Pregnancy\\n\\n\\nDiabetic Gastroparesis\\n\\n\\nDietary Supplements\\n\\n\\nExperimental Therapies\\n\\n\\nTreatment of Autonomic Dysfunction\\n\\n\\nSurgical Treatment\\n\\n\\nPancreatic Transplantation\\n\\n\\nRehabilitation\\n\\n\\nComplications of Disease\\n\\n\\nConsultations\\n\\n\\nLong-Term Monitoring\\n\\n\\nShow All\\n\\n\\n\\n\\nMedication\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nMedication Summary\\n\\n\\nNonsteroidal Anti-Inflammatory Drugs (NSAIDs)\\n\\n\\nAnalgesics, Topical\\n\\n\\nAnticonvulsant\\n\\n\\nAntidepressant, Tricyclic\\n\\n\\nAntidepressant, Selective Serotonin/norepinephrine Reuptake Inhibitor (SSNRI)\\n\\n\\nAntidepressant, Serotonin Reuptake Inhibitor\\n\\n\\nAntiarrhythmic Agent, Class I-b\\n\\n\\nProkinetic Agents\\n\\n\\nAntidepressant, Tetracyclic\\n\\n\\nSynthetic Adrenocortical Steroids\\n\\n\\nCholinergic Agent\\n\\n\\nLaxative, Bowel Evacuant\\n\\n\\nShow All\\n\\n\\n\\n\\n\\n\\nQuestions & Answers\\n\\n\\nTables\\n\\n\\nReferences\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nFind Us On\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nAbout\\n\\n\\nAbout Medscape\\n\\n\\nPrivacy Policy\\n\\n\\nEditorial Policy\\n\\n\\nCookies\\n\\n\\n\\n\\nManage Preferences\\n\\n\\n\\n\\nTerms of Use\\n\\n\\nAdvertising Policy\\n\\n\\nHelp Center\\n\\n\\n\\n\\n\\n\\nMembership\\n\\n\\nBecome a Member\\n\\n\\nAbout You\\n\\n\\nProfessional Information\\n\\n\\nNewsletters & Alerts\\n\\n\\nAdvertise\\n\\n\\n\\n\\nMarket Research\\n\\n\\n\\n\\n\\n\\nApp\\n\\n\\nMedscape\\n\\n\\n\\n\\n\\n\\nWebMD\\n Network\\n\\n\\nMedscape Live Events\\n\\n\\nWebMD\\n\\n\\nMedicineNet\\n\\n\\neMedicineHealth\\n\\n\\nRxList\\n\\n\\nWebMD Corporate\\n\\n\\nMedscape UK\\n\\n\\n\\n\\n\\n\\nEditions\\n\\n\\nEnglish\\n\\n\\nDeutsch\\n\\n\\nEspañol\\n\\n\\nFrançais\\n\\n\\nPortuguês\\n\\n\\nUK\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\t\\tAll material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.  This website also contains material copyrighted by 3rd parties.\\n\\t\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nClose\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nencoded search term (Diabetic Neuropathy) and Diabetic Neuropathy\\n\\n\\nWhat to Read Next on Medscape\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nRelated Conditions and Diseases\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n Diabetic Neuropathy\\n \\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n Fast Five Quiz: Diabetic Neuropathy Workup\\n \\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n Rapid Rx Quiz: Diabetic Neuropathy Treatments\\n \\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n Fast Five Quiz: How Much Do You Know About Diabetic Neuropathy?\\n \\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n Type 2 Diabetes Mellitus\\n \\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n Diabetic Lumbosacral Plexopathy\\n \\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n Metabolic Neuropathy\\n \\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nNews & Perspective\\n\\n\\n\\n\\n\\n\\n\\n\\nNew Perspective on Diabetic Neuropathy Emerges\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nNew Tool May Offer Diagnostic Edge for Diabetic Neuropathy\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nNew Clinical Guidance for Sjögren-Related Neuropathy\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nHiding in Plain Sight: It Looks Like Diabetic Neuropathy but Might Be Hereditary Amyloidosis\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nManaging Thyroid Adverse Events From Checkpoint Inhibitors\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nA Role for Neurologists in Diabetic Peripheral Neuropathy\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nTools\\n\\n\\nDrug Interaction Checker\\n\\n\\nPill Identifier\\n\\n\\nCalculators\\n\\n\\nFormulary\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nSlideshow\\n\\n\\n\\n\\n\\n\\n Red, Hot, and Swollen Foot in Diabetes: Charcot or No?\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nRecommended\\n\\n\\n\\n\\n\\n\\n\\r\\n        20021170337-overviewDiseases & Conditions\\n\\n\\nDiseases & Conditions\\n\\n\\n\\n\\nDiabetic Neuropathy\\n\\n\\n\\n\\n\\n\\n\\n\\n\\r\\n        2003/viewarticle/1000181\\n\\n\\n\\n\\n\\n\\nPrimary Care Best Practices in Managing Neuropathic Pain\\n\\n\\n\\n\\n\\r\\n                 0.5 CME Credits\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nYou are being redirected to\\r\\n                                Medscape Education\\r\\n                         \\n\\n\\n\\n\\nYes, take me there\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n0.5 CME\\n\\n\\nPrimary Care Best Practices in Managing Neuropathic Pain\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\r\\n        2010metanx-l-methylfolate-pyridoxal-5-phosphate-methylcobalamin-999834Drugs\\n\\n\\nDrugs\\n\\n\\n\\n\\nL-methylfolate/pyridoxal 5\\'-phosphate/methylcobalamin\\n\\n\\n\\n\\n\\n\\n\\n\\n\\r\\n        2001/viewarticle/new-perspective-diabetic-neuropathy-emerges-2024a10008ljnews\\n\\n\\nnews\\n\\n\\n\\n\\nNew Perspective on Diabetic Neuropathy Emerges\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n \\n \\n\\n\\n\\n', 'https://reference.medscape.com/article/1170337-overview'), (\"\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nA Smoker With New-Onset Pain in Both Feet\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n \\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\t\\t\\tNews & Perspective\\n\\t\\t\\n\\n\\n\\n\\n\\n\\n\\n\\t\\t\\tDrugs & Diseases\\n\\t\\t\\n\\n\\n\\n\\n\\n\\n\\n\\t\\t\\tCME & Education\\n\\t\\t\\n\\n\\n\\n\\n\\n\\n\\n\\t\\t\\tVideo\\n\\t\\t\\n\\n\\n\\n\\n\\n\\n\\n\\t\\t\\tDecision Point\\n\\t\\t\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nEdition:\\n\\n\\nEnglish\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nMedscape\\n\\n\\n\\n\\n\\n\\n\\n\\t\\t\\t\\t   English\\n\\n\\n\\n\\n\\n\\n\\n\\t\\t\\t\\t   Deutsch\\n\\n\\n\\n\\n\\n\\n\\n\\t\\t\\t\\t   Español\\n\\n\\n\\n\\n\\n\\n\\n\\t\\t\\t\\t   Français\\n\\n\\n\\n\\n\\n\\n\\n\\t\\t\\t\\t   Português\\n\\n\\n\\n\\n\\n\\n\\n\\t\\t\\t\\t   UK\\nNew\\n\\n\\n\\n\\n\\n\\nUnivadis\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nLog In\\n\\n\\nSign Up It's Free!\\n\\n\\n\\n\\n\\n\\n\\n\\t\\tEnglish Edition\\n\\n\\n\\n\\n\\n\\nMedscape\\n\\n\\n\\n\\nEnglish\\n\\n\\nDeutsch\\n\\n\\nEspañol\\n\\n\\nFrançais\\n\\n\\nPortuguês\\n\\n\\nUK\\nNew\\n\\n\\n\\n\\n\\n\\n\\n\\nUnivadis\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nX\\n\\n\\n\\n\\nUnivadis\\n \\nfrom\\n \\nMedscape\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nRegister\\n\\n\\nLog In\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nNo Results\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nNo Results\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\t\\t\\t\\tNews & Perspective\\n\\t\\t\\t\\n\\n\\n\\n\\t\\t\\t\\tDrugs & Diseases\\n\\t\\t\\t\\n\\n\\n\\n\\t\\t\\t\\tCME & Education\\n\\t\\t\\t\\n\\n\\n\\n\\t\\t\\t\\tVideo\\n\\t\\t\\t\\n\\n\\n\\n\\t\\t\\t\\tDecision Point\\n\\t\\t\\t\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nclose\\n\\n\\n\\nPlease confirm that you would like to log out of Medscape.\\nIf you log out, you will be required to enter your username and password the next time you visit.\\n\\nLog out\\n\\n\\nCancel\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nDrugs & Diseases\\n > Medscape > \\n     \\nCase Challenges\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nA Smoker With New-Onset Pain in Both Feet\\n\\n\\n\\n\\n\\n\\nHeidi Moawad, MD\\n\\n\\nDisclosures\\n\\n\\nMarch\\xa028,\\xa02024\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n \\nEditor's Note\\n:\\n \\nThe Case Challenge series includes difficult-to-diagnose conditions, some of which are not frequently encountered by most clinicians but are nonetheless important to accurately recognize. Test your diagnostic and treatment skills using the following patient scenario and corresponding questions. If you have a case that you would like to suggest for a future Case Challenge, please \\ncontact us\\n.\\n \\n\\n\\n\\n\\n\\n\\nBackground\\n\\n\\nA 60-year-old man presents with pain of recent onset in both feet. He initially thought that he might have cut his toenails too close to the skin, but the pain has persisted for over a month. He has intermittent joint pain in his hands; however, he has not received a diagnosis of arthritis. Occasionally, he takes over-the-counter nonsteroidal anti-inflammatory drugs for pain.\\n\\n\\nThe patient works as an accountant with his parents and sister in the family company that his parents established. He says that he works long hours and is always trying to get additional business. He notes that sometimes the work can be stressful, but he does not want to make any changes because he enjoys being busy.\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nHe has a family history of \\nobesity\\n and \\ntype 2 diabetes\\n; however, he has never received a diagnosis of diabetes. Nevertheless, he is concerned that his symptoms could be caused by \\ndiabetic neuropathy\\n, because his mother and brother both have this condition.\\n\\n\\n\\n\\nThe patient has smoked since he was about 25 years old. Initially, he started smoking as a way to manage stress, and then he continued because he thought it might be an effective method of preventing weight gain and subsequent type 2 diabetes. He does not specifically pay attention to his dietary intake in terms of calories or nutrients.\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nReferences\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n1\\n\\n\\n2\\n\\n\\n3\\n\\n\\n4\\n\\n\\n5\\n\\n\\n6\\n\\n\\n\\n\\n\\n\\n \\n\\n\\n\\n\\n\\n\\nNext Section\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nMedscape\\xa0©\\xa02024\\xa0WebMD, LLC\\n \\n\\n\\nAny views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.\\n\\n\\n\\n\\n\\n\\nCite this: Heidi Moawad.\\xa0A Smoker With New-Onset Pain in Both Feet\\xa0-\\xa0\\nMedscape\\n\\xa0-\\xa0Mar\\xa028,\\xa02024.\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nTables\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nReferences\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nAuthors and Disclosures\\n\\n\\n\\n\\n\\n\\nAuthors and Disclosures\\n\\n\\n\\n\\nAuthor(s)\\n\\n\\nHeidi Moawad, MD\\n\\n\\nLecturer, Case Western Reserve University, Cleveland, Ohio\\nDisclosure: Heidi Moawad, MD, has disclosed no relevant financial relationships.\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nComments\\n\\n\\n3090D553-9492-4563-8681-AD288FA52ACE\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nCommenting is limited to medical professionals. To comment please \\nLog-in\\n.\\n\\nComments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our \\nCommenting Guide\\n for further information. We reserve the right to remove posts at our sole discretion.\\n\\n\\n\\n\\nComments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our \\nCommenting Guide\\n for further information. We reserve the right to remove posts at our sole discretion.\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nMy Alerts\\n\\n\\n\\n\\nYou have already selected \\n for My Alerts\\n\\n\\n\\n\\n \\n \\nAdd Other Topics \\n \\n\\n\\n\\n\\n\\n\\n\\n\\nClick the topic below to receive emails when new articles are available.\\n\\n\\n\\n\\n \\n \\nAdd \\n \\n\\n\\n\\n\\n\\n\\n\\n\\n\\xa0\\n\\n\\n\\n\\n\\n\\n \\n\\n\\nYou've successfully added \\n to your alerts. You will receive email when new content is published.\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nShare\\n\\n\\n\\n\\n\\n\\nFacebook\\n\\n\\nTwitter\\n\\n\\nLinkedIn\\n\\n\\nWhatsApp\\n\\n\\nEmail\\n\\n\\nClose\\n\\n\\n\\n\\n\\n\\nPrint\\n\\n\\n\\n\\n\\n\\nAdd to Email Alerts \\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nprocessing....\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nWhat to Read Next on Medscape\\n\\n\\n\\n\\nSpecial Coverage: \\nCOVID-19\\n\\n\\n\\n\\nLatest\\n\\n\\nPerspective\\n\\n\\nGuidelines\\n\\n\\nDrugs & Diseases\\n\\n\\nGlobal Coverage\\n\\n\\nAdditional Resources\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nRelated Conditions & Diseases\\n\\n\\n\\n\\n\\n\\n\\n\\n Diabetic Neuropathy\\n \\n\\n\\n\\n\\n\\n\\n\\n\\n Fast Five Quiz: Diabetic Neuropathy Workup\\n \\n\\n\\n\\n\\n\\n\\n\\n\\n Rapid Rx Quiz: Diabetic Neuropathy Treatments\\n \\n\\n\\n\\n\\n\\n\\n\\n\\n Fast Five Quiz: How Much Do You Know About Diabetic Neuropathy?\\n \\n\\n\\n\\n\\n\\n\\n\\n\\n Type 2 Diabetes Mellitus\\n \\n\\n\\n\\n\\n\\n\\n\\n\\n Diabetic Lumbosacral Plexopathy\\n \\n\\n\\n\\n\\n\\n\\n\\n\\n Metabolic Neuropathy\\n \\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nLatest News & Perspective\\n\\n\\n\\n\\n\\n\\n Anti-VEGF Monotherapy is a Safe Alternative to Laser in Diabetic Retinopathy\\n\\n\\n\\n\\n\\n\\n Diabetic Ketoacidosis Common Among Latin American Children\\n\\n\\n\\n\\n\\n\\n Risk Factors for Incident Diabetic Retinopathy in T1D\\n\\n\\n\\n\\n\\n\\n\\n\\n Hiding in Plain Sight: It Looks Like Diabetic Neuropathy but Might Be Hereditary Amyloidosis\\n\\n\\n\\n\\n\\n\\n\\n\\n Managing Thyroid Adverse Events From Checkpoint Inhibitors\\n\\n\\n\\n\\n\\n\\n\\n\\n Extrahepatic Manifestations in Chronic Hepatitis C: The Impact of Diagnosis and Treatment\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nTools\\n\\n\\n\\n\\nDrug Interaction Checker\\n\\n\\nPill Identifier\\n\\n\\nCalculators\\n\\n\\nFormulary\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nSlideshow\\n\\n\\n\\n\\n\\n\\n\\n\\n Red, Hot, and Swollen Foot in Diabetes: Charcot or No?\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nRecommendations\\n\\n\\n\\n\\n\\n\\t\\t\\t\\t\\t\\t\\t\\t\\t\\t\\t2001/viewarticle/new-perspective-diabetic-neuropathy-emerges-2024a10008lj\\n\\n\\n\\n\\nNew Perspective on Diabetic Neuropathy Emerges\\n\\n\\n\\n\\nnews\\n\\n\\n\\n\\n\\n\\n\\n\\t\\t\\t\\t\\t\\t\\t\\t\\t\\t\\t2001/viewarticle/new-tool-may-offer-diagnostic-edge-diabetic-neuropathy-2024a10000ig\\n\\n\\n\\n\\nNew Tool May Offer Diagnostic Edge for Diabetic Neuropathy\\n\\n\\n\\n\\nnews\\n\\n\\n\\n\\n\\n\\n\\n\\t\\t\\t\\t\\t\\t\\t\\t\\t\\t\\t2003/viewarticle/1000181\\n\\n\\n\\n\\n\\n\\nPrimary Care Best Practices in Managing Neuropathic Pain\\n\\n\\n\\n\\n\\n\\t\\t\\t\\t\\t\\t\\t\\t\\t\\t\\t\\t\\t\\t0.5 CME Credits\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nYou are being redirected to Medscape Education\\n\\n\\n\\n\\nYes, take me there\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n0.5 CME\\n\\n\\nPrimary Care Best Practices in Managing Neuropathic Pain\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\t\\t\\t\\t\\t\\t\\t\\t\\t\\t\\t2001/viewarticle/vitamin-d-deficiency-linked-peripheral-neuropathy-2024a10005dm\\n\\n\\n\\n\\nIs Vitamin D Deficiency Linked to Peripheral Neuropathy?\\n\\n\\n\\n\\nnews\\n\\n\\n\\n\\n\\n\\n\\n\\nb:curatedcuratedHasData : false\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\t\\t\\tEmail This \\n\\n\\n\\n\\t\\t\\tFeedback\\n\\t\\t\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nHelp us make reference on Medscape the best clinical resource possible.\\n\\n\\nPlease use this form to submit your questions or comments on how to make this article more useful to clinicians.\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nYour Name:\\n \\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nYour Email:\\n \\n\\n\\n\\n\\nSend me a copy\\n\\n\\n\\n\\n\\n\\n\\n\\nRecipient's Email:\\n \\n\\n\\n\\n\\n\\n\\n\\n\\nSubject:\\n \\n\\n\\n\\n\\n\\n\\nOptional Message\\n\\n\\nComment or Suggestion\\n(Limited to 1500 Characters)\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\t\\t\\tSend\\n\\n\\n\\n\\nSend Feedback\\n\\n\\n\\n\\n\\n\\t\\t\\t\\tPlease\\ndo not\\n use this form to submit personal or patient medical information or to report adverse drug events. You are encouraged to report adverse drug event information to the FDA.\\n\\t\\t\\n\\n\\n\\n\\n\\n\\n\\n\\t\\t\\tYour Name is required.\\n\\n\\n\\n\\t\\t\\tSubject is required.\\n\\n\\n\\n\\t\\t\\tPlease enter a Recipient Address and/or check the Send me a copy checkbox.\\n\\n\\n\\n\\t\\t\\tYour email has been sent.\\n\\n\\n\\n\\t\\t\\tis an Invalid Email Address.\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nFind Us On\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nAbout\\n\\n\\nAbout Medscape\\n\\n\\nPrivacy Policy\\n\\n\\nEditorial Policy\\n\\n\\nCookies\\n\\n\\n\\n\\nManage Preferences\\n\\n\\n\\n\\nTerms of Use\\n\\n\\nAdvertising Policy\\n\\n\\nHelp Center\\n\\n\\n\\n\\n\\n\\nMembership\\n\\n\\nBecome a Member\\n\\n\\nAbout You\\n\\n\\nProfessional Information\\n\\n\\nNewsletters & Alerts\\n\\n\\nAdvertise\\n\\n\\n\\n\\nMarket Research\\n\\n\\n\\n\\n\\n\\nApp\\n\\n\\nMedscape\\n\\n\\n\\n\\n\\n\\nWebMD\\n Network\\n\\n\\nMedscape Live Events\\n\\n\\nWebMD\\n\\n\\nMedicineNet\\n\\n\\neMedicineHealth\\n\\n\\nRxList\\n\\n\\nWebMD Corporate\\n\\n\\nMedscape UK\\n\\n\\n\\n\\n\\n\\nEditions\\n\\n\\nEnglish\\n\\n\\nDeutsch\\n\\n\\nEspañol\\n\\n\\nFrançais\\n\\n\\nPortuguês\\n\\n\\nUK\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\t\\tAll material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.  This website also contains material copyrighted by 3rd parties.\\n\\t\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nClose\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n \\n \\n\\n\", 'https://www.medscape.com/viewarticle/1000569'), (\"\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nFast Five Quiz: Diabetic Neuropathy\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\t\\t\\tNews & Perspective\\n\\t\\t\\n\\n\\n\\n\\n\\n\\n\\n\\t\\t\\tDrugs & Diseases\\n\\t\\t\\n\\n\\n\\n\\n\\n\\n\\n\\t\\t\\tCME & Education\\n\\t\\t\\n\\n\\n\\n\\n\\n\\n\\n\\t\\t\\tVideo\\n\\t\\t\\n\\n\\n\\n\\n\\n\\n\\n\\t\\t\\tDecision Point\\n\\t\\t\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nEdition:\\n\\n\\nEnglish\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nMedscape\\n\\n\\n\\n\\n\\n\\n\\n\\t\\t\\t\\t   English\\n\\n\\n\\n\\n\\n\\n\\n\\t\\t\\t\\t   Deutsch\\n\\n\\n\\n\\n\\n\\n\\n\\t\\t\\t\\t   Español\\n\\n\\n\\n\\n\\n\\n\\n\\t\\t\\t\\t   Français\\n\\n\\n\\n\\n\\n\\n\\n\\t\\t\\t\\t   Português\\n\\n\\n\\n\\n\\n\\n\\n\\t\\t\\t\\t   UK\\nNew\\n\\n\\n\\n\\n\\n\\nUnivadis\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nLog In\\n\\n\\nSign Up It's Free!\\n\\n\\n\\n\\n\\n\\n\\n\\t\\tEnglish Edition\\n\\n\\n\\n\\n\\n\\nMedscape\\n\\n\\n\\n\\nEnglish\\n\\n\\nDeutsch\\n\\n\\nEspañol\\n\\n\\nFrançais\\n\\n\\nPortuguês\\n\\n\\nUK\\nNew\\n\\n\\n\\n\\n\\n\\n\\n\\nUnivadis\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nX\\n\\n\\n\\n\\nUnivadis\\n \\nfrom\\n \\nMedscape\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nRegister\\n\\n\\nLog In\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nNo Results\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nNo Results\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\t\\t\\t\\tNews & Perspective\\n\\t\\t\\t\\n\\n\\n\\n\\t\\t\\t\\tDrugs & Diseases\\n\\t\\t\\t\\n\\n\\n\\n\\t\\t\\t\\tCME & Education\\n\\t\\t\\t\\n\\n\\n\\n\\t\\t\\t\\tVideo\\n\\t\\t\\t\\n\\n\\n\\n\\t\\t\\t\\tDecision Point\\n\\t\\t\\t\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nclose\\n\\n\\n\\nPlease confirm that you would like to log out of Medscape.\\nIf you log out, you will be required to enter your username and password the next time you visit.\\n\\nLog out\\n\\n\\nCancel\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nDrugs & Diseases\\n > Medscape > \\n     \\nFast Five Quizzes\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nFast Five Quiz: How Much Do You Know About Diabetic Neuropathy?\\n\\n\\n\\n\\n\\n\\nDianna Quan, MD; Romesh Khardori, MD, PhD\\n\\n\\nDisclosures\\n\\n\\nNovember\\xa010,\\xa02016\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nNeuropathies are the most common complication of diabetes mellitus (DM), affecting up to 50% of patients with type 1 and type 2 DM. In type 1 DM, distal polyneuropathy typically becomes symptomatic after many years of chronic prolonged hyperglycemia. Conversely, patients with type 2 DM may present with distal polyneuropathy after only a few years of known poor glycemic control; sometimes these patients already have neuropathy at the time of diagnosis. Neuropathies severely decrease patients' quality of life. Furthermore, while the primary symptoms of neuropathy can be highly unpleasant, the secondary complications (eg, falls, foot ulcers, cardiac arrhythmias, and ileus) are even more serious and can lead to fractures, amputations, and even death in patients with DM. How much do you know about this condition? Test your knowledge with this quick quiz.\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n1\\n\\n\\n2\\n\\n\\n3\\n\\n\\n4\\n\\n\\n5\\n\\n\\n6\\n\\n\\n\\n\\n\\n\\n \\n\\n\\n\\n\\n\\n\\nNext Section\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nMedscape\\xa0©\\xa02016\\xa0 WebMD, LLC \\n \\n\\n\\nAny views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.\\n\\n\\n\\n\\n\\n\\nCite this: Dianna Quan,\\xa0Romesh Khardori.\\xa0Fast Five Quiz: How Much Do You Know About Diabetic Neuropathy?\\xa0-\\xa0\\nMedscape\\n\\xa0-\\xa0Jul\\xa013,\\xa02016.\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nTables\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nAuthors and Disclosures\\n\\n\\n\\n\\n\\n\\nAuthors and Disclosures\\n\\n\\n\\n\\nAuthor(s)\\n\\n\\nDianna Quan, MD\\n\\n\\nProfessor of Neurology, Director of Electromyography Laboratory, University of Colorado School of Medicine, Aurora, Colorado\\nDisclosure: Dianna Quan, MD, has disclosed no relevant financial relationships.\\n\\n\\nRomesh Khardori, MD, PhD\\n\\n\\nProfessor of Endocrinology, Director of Training Program, Division of Endocrinology, Diabetes and Metabolism, Strelitz Diabetes and Endocrine Disorders Institute, Department of Internal Medicine, Eastern Virginia Medical School, Norfolk, Virginia\\nDisclosure: Romesh Khardori, MD, PhD, has disclosed no relevant financial relationships.\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nComments\\n\\n\\n3090D553-9492-4563-8681-AD288FA52ACE\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nCommenting is limited to medical professionals. To comment please \\nLog-in\\n.\\n\\nComments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our \\nCommenting Guide\\n for further information. We reserve the right to remove posts at our sole discretion.\\n\\n\\n\\n\\nComments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our \\nCommenting Guide\\n for further information. We reserve the right to remove posts at our sole discretion.\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nMy Alerts\\n\\n\\n\\n\\nYou have already selected \\n for My Alerts\\n\\n\\n\\n\\n \\n \\nAdd Other Topics \\n \\n\\n\\n\\n\\n\\n\\n\\n\\nClick the topic below to receive emails when new articles are available.\\n\\n\\n\\n\\n \\n \\nAdd \\n \\n\\n\\n\\n\\n\\n\\n\\n\\n\\xa0\\n\\n\\n\\n\\n\\n\\n \\n\\n\\nYou've successfully added \\n to your alerts. You will receive email when new content is published.\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nShare\\n\\n\\n\\n\\n\\n\\nFacebook\\n\\n\\nTwitter\\n\\n\\nLinkedIn\\n\\n\\nWhatsApp\\n\\n\\nEmail\\n\\n\\nClose\\n\\n\\n\\n\\n\\n\\nPrint\\n\\n\\n\\n\\n\\n\\nAdd to Email Alerts \\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nprocessing....\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nWhat to Read Next on Medscape\\n\\n\\n\\n\\nSpecial Coverage: \\nCOVID-19\\n\\n\\n\\n\\nLatest\\n\\n\\nPerspective\\n\\n\\nGuidelines\\n\\n\\nDrugs & Diseases\\n\\n\\nGlobal Coverage\\n\\n\\nAdditional Resources\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nRelated Conditions & Diseases\\n\\n\\n\\n\\n\\n\\n\\n\\n Diabetic Neuropathy\\n \\n\\n\\n\\n\\n\\n\\n\\n\\n Fast Five Quiz: Diabetic Neuropathy Workup\\n \\n\\n\\n\\n\\n\\n\\n\\n\\n Rapid Rx Quiz: Diabetic Neuropathy Treatments\\n \\n\\n\\n\\n\\n\\n\\n\\n\\n Fast Five Quiz: How Much Do You Know About Diabetic Neuropathy?\\n \\n\\n\\n\\n\\n\\n\\n\\n\\n Type 2 Diabetes Mellitus\\n \\n\\n\\n\\n\\n\\n\\n\\n\\n Diabetic Lumbosacral Plexopathy\\n \\n\\n\\n\\n\\n\\n\\n\\n\\n Metabolic Neuropathy\\n \\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nLatest News & Perspective\\n\\n\\n\\n\\n\\n\\n Anti-VEGF Monotherapy is a Safe Alternative to Laser in Diabetic Retinopathy\\n\\n\\n\\n\\n\\n\\n Diabetic Ketoacidosis Common Among Latin American Children\\n\\n\\n\\n\\n\\n\\n Risk Factors for Incident Diabetic Retinopathy in T1D\\n\\n\\n\\n\\n\\n\\n\\n\\n Hiding in Plain Sight: It Looks Like Diabetic Neuropathy but Might Be Hereditary Amyloidosis\\n\\n\\n\\n\\n\\n\\n\\n\\n Managing Thyroid Adverse Events From Checkpoint Inhibitors\\n\\n\\n\\n\\n\\n\\n\\n\\n Extrahepatic Manifestations in Chronic Hepatitis C: The Impact of Diagnosis and Treatment\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nTools\\n\\n\\n\\n\\nDrug Interaction Checker\\n\\n\\nPill Identifier\\n\\n\\nCalculators\\n\\n\\nFormulary\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nSlideshow\\n\\n\\n\\n\\n\\n\\n\\n\\n Red, Hot, and Swollen Foot in Diabetes: Charcot or No?\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nRecommendations\\n\\n\\n\\n\\n\\n\\t\\t\\t\\t\\t\\t\\t\\t\\t\\t\\t2001/viewarticle/new-perspective-diabetic-neuropathy-emerges-2024a10008lj\\n\\n\\n\\n\\nNew Perspective on Diabetic Neuropathy Emerges\\n\\n\\n\\n\\nnews\\n\\n\\n\\n\\n\\n\\n\\n\\t\\t\\t\\t\\t\\t\\t\\t\\t\\t\\t2001/viewarticle/new-tool-may-offer-diagnostic-edge-diabetic-neuropathy-2024a10000ig\\n\\n\\n\\n\\nNew Tool May Offer Diagnostic Edge for Diabetic Neuropathy\\n\\n\\n\\n\\nnews\\n\\n\\n\\n\\n\\n\\n\\n\\t\\t\\t\\t\\t\\t\\t\\t\\t\\t\\t2003/viewarticle/1000181\\n\\n\\n\\n\\n\\n\\nPrimary Care Best Practices in Managing Neuropathic Pain\\n\\n\\n\\n\\n\\n\\t\\t\\t\\t\\t\\t\\t\\t\\t\\t\\t\\t\\t\\t0.5 CME Credits\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nYou are being redirected to Medscape Education\\n\\n\\n\\n\\nYes, take me there\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n0.5 CME\\n\\n\\nPrimary Care Best Practices in Managing Neuropathic Pain\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\t\\t\\t\\t\\t\\t\\t\\t\\t\\t\\t2001/viewarticle/vitamin-d-deficiency-linked-peripheral-neuropathy-2024a10005dm\\n\\n\\n\\n\\nIs Vitamin D Deficiency Linked to Peripheral Neuropathy?\\n\\n\\n\\n\\nnews\\n\\n\\n\\n\\n\\n\\n\\n\\nb:recommendationscuratedHasData : false\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\t\\t\\tEmail This \\n\\n\\n\\n\\t\\t\\tFeedback\\n\\t\\t\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nHelp us make reference on Medscape the best clinical resource possible.\\n\\n\\nPlease use this form to submit your questions or comments on how to make this article more useful to clinicians.\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nYour Name:\\n \\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nYour Email:\\n \\n\\n\\n\\n\\nSend me a copy\\n\\n\\n\\n\\n\\n\\n\\n\\nRecipient's Email:\\n \\n\\n\\n\\n\\n\\n\\n\\n\\nSubject:\\n \\n\\n\\n\\n\\n\\n\\nOptional Message\\n\\n\\nComment or Suggestion\\n(Limited to 1500 Characters)\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\t\\t\\tSend\\n\\n\\n\\n\\nSend Feedback\\n\\n\\n\\n\\n\\n\\t\\t\\t\\tPlease\\ndo not\\n use this form to submit personal or patient medical information or to report adverse drug events. You are encouraged to report adverse drug event information to the FDA.\\n\\t\\t\\n\\n\\n\\n\\n\\n\\n\\n\\t\\t\\tYour Name is required.\\n\\n\\n\\n\\t\\t\\tSubject is required.\\n\\n\\n\\n\\t\\t\\tPlease enter a Recipient Address and/or check the Send me a copy checkbox.\\n\\n\\n\\n\\t\\t\\tYour email has been sent.\\n\\n\\n\\n\\t\\t\\tis an Invalid Email Address.\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nFind Us On\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nAbout\\n\\n\\nAbout Medscape\\n\\n\\nPrivacy Policy\\n\\n\\nEditorial Policy\\n\\n\\nCookies\\n\\n\\n\\n\\nManage Preferences\\n\\n\\n\\n\\nTerms of Use\\n\\n\\nAdvertising Policy\\n\\n\\nHelp Center\\n\\n\\n\\n\\n\\n\\nMembership\\n\\n\\nBecome a Member\\n\\n\\nAbout You\\n\\n\\nProfessional Information\\n\\n\\nNewsletters & Alerts\\n\\n\\nAdvertise\\n\\n\\n\\n\\nMarket Research\\n\\n\\n\\n\\n\\n\\nApp\\n\\n\\nMedscape\\n\\n\\n\\n\\n\\n\\nWebMD\\n Network\\n\\n\\nMedscape Live Events\\n\\n\\nWebMD\\n\\n\\nMedicineNet\\n\\n\\neMedicineHealth\\n\\n\\nRxList\\n\\n\\nWebMD Corporate\\n\\n\\nMedscape UK\\n\\n\\n\\n\\n\\n\\nEditions\\n\\n\\nEnglish\\n\\n\\nDeutsch\\n\\n\\nEspañol\\n\\n\\nFrançais\\n\\n\\nPortuguês\\n\\n\\nUK\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\t\\tAll material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.  This website also contains material copyrighted by 3rd parties.\\n\\t\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nClose\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n \\n \\n\\n\", 'https://www.medscape.com/viewarticle/865719')]\n"
          ]
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "### Add Data to Vector Database"
      ],
      "metadata": {
        "id": "O0KpevNcfjK-"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "embeddings = OpenAIEmbeddings(model=\"text-embedding-ada-002\")\n",
        "\n",
        "my_activeloop_org_id = \"test\"\n",
        "my_activeloop_dataset_name = \"test_ds\"\n",
        "dataset_path = f\"hub://{my_activeloop_org_id}/{my_activeloop_dataset_name}\"\n",
        "deeplake_vector_store = DeepLake(dataset_path=dataset_path, embedding_function=embeddings)"
      ],
      "metadata": {
        "id": "KSx1HbI8gKLK"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "def split_text_and_metadata(documents: List[Tuple[str, str]]) -> Tuple[List[str], List[Dict[str, str]]]:\n",
        "    \"\"\"Split text on chunks and return it with list of sources metadata\"\"\"\n",
        "    splitter = RecursiveCharacterTextSplitter(chunk_size=2000, chunk_overlap=200)\n",
        "    split_texts = []\n",
        "    metadatas = []\n",
        "    for doc, link in documents:\n",
        "        cleaned_doc = '\\n'.join([line for line in doc.split('\\n') if line.strip()])\n",
        "        chunks = splitter.split_text(cleaned_doc)\n",
        "        split_texts.extend(chunks)\n",
        "        metadatas.extend([{\"source\": link}] * len(chunks))\n",
        "    return split_texts, metadatas\n",
        "\n",
        "\n",
        "def add_documents_to_store_by_query(query: str) -> str:\n",
        "    \"\"\" Searches for relevant documents that may contain the answer to the query\"\"\"\n",
        "    documents = fetch_medscape_content(query)\n",
        "    if len(documents) == 0:\n",
        "      return [], []\n",
        "    new_documents = []\n",
        "    for (doc, link) in documents:\n",
        "        if not next((d for d in deeplake_vector_store.vectorstore.dataset['metadata'].data()['value'] if d.get('source') == link), None):\n",
        "          new_documents.append((doc, link))\n",
        "        else:\n",
        "          print(f\"{link} is already in db\")\n",
        "\n",
        "    texts, metadatas = split_text_and_metadata(new_documents)\n",
        "    deeplake_vector_store.add_texts(texts=texts, metadatas=metadatas)\n",
        "    return texts, metadatas"
      ],
      "metadata": {
        "id": "MWLs6Uigfno7"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "splitter = RecursiveCharacterTextSplitter(chunk_size=1000, chunk_overlap=200)\n",
        "split_texts = []\n",
        "metadatas = []\n",
        "for doc, link in documents:\n",
        "    chunks = splitter.split_text(doc)\n",
        "    split_texts.extend(chunks)\n",
        "    metadatas.extend([{\"source\": link}] * len(chunks))"
      ],
      "metadata": {
        "id": "7-z-fnyJIesW"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "add_documents_to_store_by_query(\"manage a newly diagnosed patient with atrial fibrillation\")"
      ],
      "metadata": {
        "id": "JisA-Tx79IIf"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "source": [
        "### Get Answer from DB"
      ],
      "metadata": {
        "id": "C_NuE5jHgMPV"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "def retrieve_documents(query: str) -> str:\n",
        "      retrieved_docs_similarity = deeplake_vector_store.similarity_search(query, k=7)\n",
        "      if len(retrieved_docs_similarity) == 0:\n",
        "          return []\n",
        "      retrieved_docs_with_score = deeplake_vector_store.similarity_search_with_score(query, k=7)\n",
        "      scores = retrieved_docs_with_score[0][1]\n",
        "      retrieved_docs_similarity = np.array(retrieved_docs_similarity)[scores >= 0.8]\n",
        "      return retrieved_docs_similarity\n",
        "\n",
        "def get_answer(query: str):\n",
        "  retireved_documents = retrieve_documents(query)\n",
        "  # if len(result['sources']) == 0: # fast inmemory answering\n",
        "  if len(retireved_documents) < 2:\n",
        "    print(\"MEMORY ANSWERING\")\n",
        "    split_texts, metadatas = add_documents_to_store_by_query(query)\n",
        "    if len(split_texts) == 0:\n",
        "      print(\"NO results\")\n",
        "      return None\n",
        "    in_memory_vector_store = FAISS.from_texts(texts=split_texts, embedding=embeddings, metadatas=metadatas)\n",
        "  else:\n",
        "    in_memory_vector_store = FAISS.from_documents(retireved_documents, embeddings)\n",
        "\n",
        "  in_memory_retriever = in_memory_vector_store.as_retriever(search_type=\"similarity\", search_kwargs={\"k\": 5})\n",
        "  in_memory_qa_chain = RetrievalQAWithSourcesChain.from_llm(llm=llm, retriever=in_memory_retriever)\n",
        "\n",
        "  result = in_memory_qa_chain({\"question\": query})\n",
        "  return result"
      ],
      "metadata": {
        "id": "8_uWSdLMgFrd"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "llm = ChatOpenAI(model=\"gpt-3.5-turbo\", temperature=0.7, max_tokens=1500)\n",
        "deeplake_retriever = deeplake_vector_store.as_retriever(search_type=\"similarity\", search_kwargs={\"k\": 5})\n",
        "qa_chain = RetrievalQAWithSourcesChain.from_llm(llm=llm, retriever=deeplake_retriever)\n",
        "deeplake_retriever.search_kwargs[\"distance_metric\"] = \"cos\""
      ],
      "metadata": {
        "collapsed": true,
        "id": "m1vpQOqB6L1z"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "source": [
        "### Results\n",
        "As well as processing time measurements"
      ],
      "metadata": {
        "id": "j5BG1HN1jXOi"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "%%time\n",
        "answer = get_answer(\"What are the signs and symptoms that indicate worsening heart failure\")\n",
        "# answer = get_answer(\"manage a newly diagnosed patient with atrial fibrillation\")\n",
        "# answer = get_answer(\"treatment options for an asymptomatic man with elevated PSA levels\")\n",
        "# answer = get_answer(\"underlying cause of diarrhea and chills in a patient with COPD\")\n",
        "\n",
        "#90sec for new texts\n",
        "#40sec for db preloaded"
      ],
      "metadata": {
        "id": "wCLORsZ8U4PC",
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "outputId": "3cdfbfaa-08e2-4e57-e23e-8731e9161378"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "[0.82154846 0.8165041  0.81514907 0.8147638  0.8145889  0.81025535\n",
            " 0.8101315 ]\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "/usr/local/lib/python3.10/dist-packages/langchain_core/_api/deprecation.py:139: LangChainDeprecationWarning: The method `Chain.__call__` was deprecated in langchain 0.1.0 and will be removed in 0.3.0. Use invoke instead.\n",
            "  warn_deprecated(\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "CPU times: user 1.64 s, sys: 165 ms, total: 1.8 s\n",
            "Wall time: 15.7 s\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "answer"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "PfoqJyVewPUT",
        "outputId": "1ff3b13a-0ddb-45b8-fb6c-2a2a71a3c4b2"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "{'question': 'What are the signs and symptoms that indicate worsening heart failure',\n",
              " 'answer': 'Signs and symptoms that indicate worsening heart failure include decompensated congestive heart failure (CHF), abrupt onset of episodic palpitations with shortness of breath, irregularly irregular beats on auscultation, high heart rate (140 bpm), cool, diaphoretic, and hypotensive episodes, crackles in the lungs from pulmonary vascular congestion, fever, chills, malaise, persistent productive cough with rust-colored sputum tinged with green, and the use of accessory muscles for respiration.\\n',\n",
              " 'sources': 'https://www.medscape.com/viewarticle/979747, https://reference.medscape.com/article/151066-overview, https://www.medscape.com/viewarticle/989470, https://reference.medscape.com/article/159222-overview'}"
            ]
          },
          "metadata": {},
          "execution_count": 18
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "%%time\n",
        "retrieve_documents(\"manage a newly diagnosed patient with atrial fibrillation\")"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "fEEYj2C9p6qm",
        "outputId": "775c4d17-f022-45df-87f2-c2b5c1c24161"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "[0.8290435  0.7870921  0.786822   0.7736869  0.76932687]\n",
            "CPU times: user 278 ms, sys: 22.5 ms, total: 301 ms\n",
            "Wall time: 5.14 s\n"
          ]
        },
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "array([Document(page_content='atrial fibrillation\\n, and a recent \\npercutaneous coronary intervention\\n (PCI) for an ST-segment elevation \\nmyocardial infarction\\n (STEMI).\\nOne day before he presented to the ED, the patient experienced sudden onset of progressively worsening dyspnea upon exertion, which was accompanied by increased fatigue. The shortness of breath occurred while he was walking around the house and climbing a flight of stairs. Sitting down eased his symptoms. He states that the dyspnea upon exertion represents an increase from his baseline condition.\\nThe patient says that he has used two pillows while sleeping for \"as long as I can remember.\" He does not recall any episodes of waking up at night and gasping for air. He denies any fever, chills, cough, recent sick contacts, or respiratory tract infections. He does not have any chest pain or leg swelling.\\nThe patient also reports that his stools have become darker over the past 3 days; the consistency is normal. He has not had any associated abdominal pain, painful defecation, recent diarrhea, or change in his bowel and bladder habits. He does not take over-the-counter pain medications. The results of a \\ncolonoscopy\\n 2 years prior were normal. He has not had similar stool darkening in the past.\\nFor more than 30 years, the patient smoked two packs of cigarettes per day. He received a diagnosis of \\nchronic obstructive pulmonary disease\\n (COPD). He does not take any medications for COPD or use oxygen at home. He has no history of substance use (including marijuana) or alcohol consumption.\\nHe takes \\napixaban\\n for atrial fibrillation, which was diagnosed 5 years earlier. He underwent PCI for a STEMI with placement of a drug-eluting stent in the right coronary artery 45 days ago. \\nAspirin\\n and \\nclopidogrel\\n were started after the procedure. He does not take any other medications.\\nThe patient has a family history of \\ninflammatory bowel disease\\n (IBD) in his father and \\ndiverticulosis\\n in his mother.\\nReferences\\n1\\n2\\n3\\n4\\n5\\n6\\nNext Section', metadata={'source': 'https://www.medscape.com/viewarticle/948838'})],\n",
              "      dtype=object)"
            ]
          },
          "metadata": {},
          "execution_count": 39
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "%%time\n",
        "get_answer(\"severe headacke pills\")"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "HXKoq-MiKfgp",
        "outputId": "3921d108-728e-4796-ed69-7d999d2a6eba"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "CPU times: user 280 ms, sys: 14.1 ms, total: 295 ms\n",
            "Wall time: 10.3 s\n"
          ]
        },
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "{'question': 'severe headacke pills',\n",
              " 'answer': 'There is no specific mention of severe headache pills in the information provided.\\n',\n",
              " 'sources': ''}"
            ]
          },
          "metadata": {},
          "execution_count": 59
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "result = get_answer(\"symptoms of diabetes\")\n",
        "result"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "_8KQG5GJIu2V",
        "outputId": "142e137c-3716-43a8-f48e-c13c3d28c6e8"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "{'question': 'symptoms of diabetes',\n",
              " 'answer': 'Symptoms of diabetes include hyperglycemia, glycosuria, polydipsia, unexplained weight loss, nonspecific malaise, and symptoms of ketoacidosis. Diabetic peripheral neuropathy causes sensorial and motor symptoms. \\n',\n",
              " 'sources': 'https://reference.medscape.com/article/919999-overview, http://reference.medscape.com/features/slideshow/dmc/'}"
            ]
          },
          "metadata": {},
          "execution_count": 113
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "### Run the Chatbot"
      ],
      "metadata": {
        "id": "U0j8qomHjNr0"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "st.title(f\"Chat with Medscape\")\n",
        "if \"generated\" not in st.session_state:\n",
        "\tst.session_state[\"generated\"] = [\"i am ready to help you\"]\n",
        "\n",
        "if \"past\" not in st.session_state:\n",
        "\tst.session_state[\"past\"] = [\"hello\"]\n",
        "\n",
        "user_input = st.text_input(\"\", key=\"input\")\n",
        "\n",
        "if user_input:\n",
        "\toutput = qa.run(user_input)\n",
        "\tst.session_state.past.append(user_input)\n",
        "\tst.session_state.generated.append(output)\n",
        "\n",
        "if st.session_state[\"generated\"]:\n",
        "\tfor i in range(len(st.session_state[\"generated\"])):\n",
        "\t\tmessage(st.session_state[\"past\"][i], is_user=True, key=str(i) + \"_user\")\n",
        "\t\tmessage(st.session_state[\"generated\"][i], key=str(i))"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "kTBGLQvKpyg2",
        "outputId": "a4bd1648-8202-4f4b-81c9-272295e83711"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "2024-06-13 12:52:08.971 \n",
            "  \u001b[33m\u001b[1mWarning:\u001b[0m to view this Streamlit app on a browser, run it with the following\n",
            "  command:\n",
            "\n",
            "    streamlit run /usr/local/lib/python3.10/dist-packages/colab_kernel_launcher.py [ARGUMENTS]\n",
            "2024-06-13 12:52:08.972 `label` got an empty value. This is discouraged for accessibility reasons and may be disallowed in the future by raising an exception. Please provide a non-empty label and hide it with label_visibility if needed.\n"
          ]
        }
      ]
    }
  ]
}